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論文の内容の要旨 
個別化医療開発における企業の能力 (Corporate Capability for Personalized Medicine Development) 
張家 銘 
 
1. はじめに 
個別化医療とは、治療を行う前にバイオマーカーを調べることで、患者一人一人にあった治療方法･医薬
品を提供することを可能にする医療モデルである。薬物治療において個別化医療を実現させるには、医薬品の
効果予測や安全性予測等を目的としたバイオマーカーを特定できる検査薬、いわゆるコンパニオン診断薬
（Companion Diagnostics; CoDx）が必要不可欠である。このことから、個別化医療の開発において、医薬品と
CoDx の同時開発は一つの重要な成功要因であり、その開発における企業の能力を正確に把握することは、製薬
企業および診断薬企業にとって、戦略やポートフォリオマネジメントを考える上で、大変重要である。個別化
医療の開発における成功要因として、バイオマーカーの早期発見や製薬企業と診断薬企業の早期連携等が、先
行研究において挙げられた[1]。しかしながら、これらを実施する上で必要な企業の能力については、先行研究に
おいて、明確に定義された上で評価が行われたことがない。したがって、本研究では以下に示す二つの研究の
実施を通じて、製薬企業と診断薬企業における個別化医療の開発力の実態を評価できる分析枠組みを新たに構
築することを目的とした。 
 
2. Study 1：製薬会社における個別化医療医薬品の開発力の評価[3] 
＜背景と目的＞ 製薬企業における医薬品開発に焦点を当てた場合、医薬品と CoDx の同時開発におけるプロ
セスの細分化については、先行研究において議論されてきた[2] [4]。また、医薬品と CoDx の同時開発を実現させ
る方法として、製薬企業にとっては、社外診断薬企業と提携する方法と社内診断薬部門と提携する方法が存在
するが、同時開発プロセスの複雑さを指摘し、診断部門の内製化が有利であるとの提言が先行研究においてな
されてきた[5]。しかしながら、製薬企業の個別化医療医薬品の開発力（personalized medicine development capability; 
PMD capability）の構成要素を定義した上で、それらと PMD capability との関連性について定量的に議論された
研究は、これまで報告されたことがない。そこで、Study 1 では、一つの研究モデルを構築し、製薬企業におけ
る PMD capability と関連する構成要素間の因果関係について定量的に評価することとした。 
 
＜方法＞ 最初に、PMD capability に影響及ぼすと考えられる三つの構成要素として、new product development 
capability（NPD capability）、capability of CoDx co-development with external parties（external CoDxD capability）、
capability of CoDx co-development with internal organization（internal CoDxD capability）があると定義した。次に、
PMD capability と各構成要素間の因果関係について 6 つの仮説を立て、それらを Structural Equation Modeling
（SEM）分析を用いて検証すべくそれぞれの因子に観測変数を設定し、一つの研究モデルを構築した（Figure 1）。 
  
＜結果と考察＞ 研究の対象サンプルは、個別化医療医薬品の開発に投資実績のある 15 社の製薬会社に限定し
た。得られたデータと構築された研究モデルに基づき SEM 分析を行ったところ、Figure 2 に示す結果が得られ
た。モデルの適合度を示す四つの指標（CFI、GFI、RMR、RMSEA）はいずれも基準値を超え、構築されたモデ
ルは高い適合度を有していることが検証された。各因子間の関係性については、係数が有意であり、且つ、0.5
以上であった場合に因果関係があると定義した。その結果、各因子間の関係は Figure 3 に示す形で簡易化する
ことができ、PMD capability に影響与えるクリティカルパスは、NPD capability を起点に external CoDxD capability
を介していることを見出した。 
 
 
 
この結果については、二点の考察を行った。第一は NPD capability が PMD capability に与える影響につい
てである。本研究では NPD capability から PMD capability への因果関係として、直接的効果（仮説 1）と、external 
CoDxD capability あるいは internal CoDxD capability を介した間接的な効果があると仮定（仮説 2～5）したが、
分析の結果、external CoDxD capability を介した間接的な効果のみ有していることが見出された。このことは、
個別化医療医薬品の開発において、基礎となる NPD capability が高いことは必要条件ではあったが、十分条件で
はなかったことが確認された。すなわち、NPD capability が高い企業全てが個別化医療の開発においてイノベー
ションが進んでいることではなく、CoDxD capability が高い一部の企業のみ特に PMD capability が高いことが、
本研究を通じて定量的な評価によって初めて示唆された。 
第二は、external と internal CoDxD capability の PMD capability に与える影響についてである。SEM 分析の
結果、PMD capability に与える効果として、社内診断薬部門との連携に頼る internal CoDxD capability よりも社外
診断薬企業との連携に頼る external CoDxD capability の方が強い因果関係を有していることが示された。この結
果を説明する一つの理由として、CoDx 開発には、バイオマーカーを特定するのに合った柔軟、且つ、コスト効
果に優れた多種多様なプラットフォームが必要とされていると考えられる。すなわち、社内に診断薬部門を有
していても、これら全ての CoDx 開発に伴う技術をカバーすることは困難であり、内部化連携の可否にかかわ
らず、当該医薬品にとっての最適な CoDx 同時開発ができるよう、優れた external CoDxD capability を有してい
る必要があると、本研究の結果から示唆された。 
 
3. Study 2：診断薬会社における CoDx の開発力の評価[6] 
＜背景と目的＞ Study 1 では製薬企業における PMD capability と各構成要素間の因果関係については定量的に
評価できたものの、医薬品と CoDx の同時開発に伴う、診断薬企業における CoDx の開発力の分析は依然不明確
のままである。CoDx 開発に関しては、開発プロセスの分解について議論されたものは多く存在するが[4] [7]、そ
れに必要な診断薬企業の能力について定義・評価された研究は、これまで報告されたことがない。そこで、Study 
2 では、CoDx 開発における診断薬企業の knowledge management capability を細分化し、その上で、現在の実態を
評価することを目的にした。 
  
＜方法＞ 企業における knowledge management を分析する際、多くの研究において、ステージを exploration と
exploitation に、knowledge ソースを internal と external に細分化して議論してきた[8] [9]。これらは一般論としては
有用であるが、CoDx 開発においては、Rajan ら(2012)が指摘するように、knowledge が biomarker knowledge、
platform knowledge、diagnostic kit knowledge の三つの要素から構成されていること[10]、そして、それらを統合す
る必要があることから、一般論では説明することが不十分であると考えられる。そこで、本研究では既存のフ
レームワークに加え、三つの構成要素を表現するために knowledge exploration ステージを biomarker、platform、
diagnostic kit に細分化し、更に、それらを統合し製薬企業と共に CoDx knowledge として発展させる中間段階を
knowledge expansion ステージとして追加し、CoDx 開発に必要な knowledge management capability として、Table 1
に示すような形で一つの新しいフレームワークとして提示した。次に、二つの事例研究の実施を通じて、本フ
レームワークの分解能の妥当性を確認し、そして、CoDx 開発に伴って診断薬企業が利用している能力とその知
識ソースの実態を分析することとした。 
 
＜結果と考察＞ 一つ目の事例研究として、BRAF V600 変異の有無を特定することを目的に、それぞれ Roche 
Diagnostics 社と bioMérieux 社によって開発・市販された、Cobas® 4800 BRAF V600 mutation test と THxID™ BRAF 
kit をサンプルとし、本研究のフレームワークの分解能の妥当性について検証した。その結果、Table 2 に示すよ
うに、いずれの場合においても、本フレームワークを用いることより、CoDx 開発に用いられたそれぞれの診断
薬企業の能力を明確化し、且つ、二つの事例間の差分についても比較することも可能にした。 
  
二つ目の事例研究は、過去 10 年間に FDA により承認された全 CoDx サンプルとして、CoDx 開発に用い
た企業の能力の傾向について分析した（Table 3）。その結果、biomarker knowledge exploration においては、全て
の事例において、BM absorptive capacity を利用していることが示された。すなわち、Biomarker knowledge につ
いては、殆どが製薬会社によって生みだされ、診断薬会社はそれを自社に吸収し CoDx 開発に利用しているこ
とが示唆された。一方で、platform と diagnostic kit の knowledge exploration においては internal な能力を利用し
て knowledge を探索していることが主流であるものの、そのバラツキが大きいことが示された。これに対する
考察としては、Study 1 と同様、CoDx 開発には最先端な技術が必要とされ、一社のみでは必要な knowledge 全
てをカバーできない実態を反映しているものと考えられる。最後に、knowledge expansion と exploitation におい
ては、全ての事例において、internal な能力を利用して、knowledge を発展・活用していることが示された。こ
れは、knowledge expansion 段階と knowledge exploitation 段階は、CoDx 開発における診断薬企業の中核的能力で
あり、他社へ外注・ライセンシングすることなく、自社内で実施していることを示唆していると考えられる。 
  
4. 結論 
本研究では、個別化医療開発における企業の能力について明確化すべく、二つの研究を実施した。Study 1
では製薬企業に着眼点を置き、NPD capabilityを起点に external CoDxD capabilityを介するルートがPMD capability
に影響与えるクリティカルパスであることを定量的に検証し、現状においては、診断部門の内製化よりも社外
診断薬企業との連携の方が、個別化医療医薬品の開発において有効であることが示唆された。次に、Study 2 に
おいては診断薬企業に着眼点を置き、CoDx 開発に必要な診断薬企業の能力を評価するツールとして分析フレー
ムワークを新たに構築し、その能力を知識の源泉という観点から内外に区分し、三段階のステージに分解して
観測した。その結果、診断薬企業の中核的な能力として内部化される部分と技術の進展が早く外部に知識ソー
スを依存する傾向が高い部分に区分できることを見出した。また、この二つの研究結果を併せて考察すること
により、製薬企業の external CoDxD capability と診断薬企業の BM absorptive capacity は、医薬品と CoDx の同時
開発に伴う製薬企業と診断薬企業間の連携に重要な役割を果たしていることが示唆された。更には、CoDx 開発
には最先端な技術を必要とすることから、現状、一社のみでは全ての必要技術を賄うことが困難であることも
この研究結果から示唆された。 
以上のことから、本研究は製薬企業と診断薬企業の両方面から個別化医療開発の企業の能力を評価できる
枠組みを初めて構築し、その妥当性・有用性を検証した。このことにより、両産業における企業の個別化医療
の開発力を評価することを可能にし、且つ、その傾向をモニタリングすることができることから、企業戦略の
立案やポートフォリオマネジメント上も有用であると考えられる。 
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Abstract 
Personalized medicine is a medical model that aims to achieve optimal medical 
outcomes by helping physicians and patients choose the disease management 
approaches likely to work best based on the patient’s unique genetic and environmental 
profile. In the field of pharmacotherapy, the techniques of utilizing a stratified 
approach and identifying groups of patients based on certain biologic characteristics or 
biomarkers using companion diagnostics (CoDx) can potentially be more efficient and 
effective than traditional approaches, while reducing undesirable drug interactions and 
side effects. 
When evaluating corporate strategies in the pharmaceutical and diagnostic 
industries, it is essential to precisely understand corporate capability for personalized 
medicine. Therefore, in this thesis, two studies are conducted to describe corporate 
capability of personalized medicine development from pharmaceutical and diagnostic 
firms’ points of view, respectively. The outline for this thesis is provided below. 
In Chapter 1, the background of personalized medicine and the positioning of this 
thesis are described. 
Subsequently, in Chapter 2, a literature review delineates previous works on 
corporate capability as related to product development. 
In Chapter 3, a model is developed to illustrate the corporate capability of 
personalized medicine development in the pharmaceutical industry (PMD capability). 
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Firstly, three key PMD capability influencing factors are defined, including corporate 
capability for new product development (NPD capability), corporate capability of 
CoDx co-development with external parties (External CoDxD capability), and 
corporate capability of CoDx co-development with an internal organization (Internal 
CoDxD capability). Based on these concepts, a research model is developed. 
Subsequently, structural equation modeling (SEM) analysis reveals that a good fit of 
the model is successfully achieved. In this model, results indicate that the critical path 
contributing to PMD capability runs from NPD capability via External CoDxD 
capability rather than via Internal CoDxD capability. 
Next, Chapter 4 develops a framework to illustrate diagnostic firms’ corporate 
knowledge sourcing and management capability of CoDx development. The purpose 
of this model is to provide an understanding of corporate capability of personalized 
medicine development in the diagnostic industry. First, three key knowledge elements 
necessary for CoDx development are defined. Second, a unique framework is 
constructed to detail firms’ ability to manage this knowledge. Finally, the proposed 
framework is applied to several CoDx development cases to test its practical utility. In 
the end, the study results indicate that this framework can improve understanding and 
track trends in corporate knowledge sourcing and management capability for CoDx 
development in the diagnostic industry. 
Finally, Chapter 5 provides a summary and an integrated conclusion of this thesis. 
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1.1. Background of personalized medicine 
In recent years, healthcare delivery has changed substantially. Traditional 
approaches to therapeutics discovery and development are pathology and 
symptom-based, with the objective of finding a blockbuster drug (drugs with sales 
exceeding $1 billion USD) that is effective for all patients suffering from a disease or 
condition (Zhang and Zhang, 2013). However, this paradigm is no longer a viable 
option for pharmaceutical companies because only a fraction of patients responds to 
traditional therapies and healthcare spending is under intense pressure (Desiere et al., 
2013). For example, 38% of depression patients, 50% of arthritis patients, 40% of 
asthma patients, and 43% of diabetic patients will not respond to initial treatment 
(Personalized Medicine Coalition, 2014; Spear et al., 2001) (Figure 1). In addition, the 
demand for evidence-based therapeutics by regulatory authorities are becoming 
increasingly pressing for the industry, resulting in the need to adopt a novel and more 
appropriate paradigm for drug discovery and development (Amir-Aslani and 
Mangematin, 2010). 
This paradigm change is closely associated with an increased interest in the 
discovery of biomarkers. According to the National Institutes of Health Biomarkers 
Definitions Working Group, a biomarker is defined as ‘a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention’ 
(Biomarkers Definitions Working Group, 2001). Biomarkers can play a crucial role in 
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understanding patient differences and help the business model of drug discovery to 
move away from mass-marketed products towards targeted treatments.  
 
 
Figure 1.  Percentage of the patient population for which a particular drug in a class 
is ineffective, on average. (source: Personalized Medicine Coalition, 2014) 
 
The first step in this paradigm change is the identification of biomarkers that link 
disease biology to the therapeutic product in question. This requires an in-depth 
understanding of the pathways involved in the disease process, detailed 
characterization of drug targets and identification of biomarkers with a demonstrated 
relationship with and significance in the disease process, the mode of action of the 
drug, and the importance of the role played in the relevant patient population (Desiere, 
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2013). Certainly, this is a trend at the clinical development stage. As shown in Figure 2, 
the number and rate of clinical trials including biomarker assessments have apparently 
increased during last decade, implying that many research efforts are currently utilized 
in this era. Furthermore, to date, the labeling of more than 100 the US Federal Drug 
Administration (FDA) approved drugs contain information on genomic biomarkers 
(e.g. gene variants, functional deficiencies, expression changes, chromosomal 
abnormalities) (FDA, 2014) (Figure 3). Some, but not all, of the labeling include 
specific actions to be taken based on genetic information. 
 
 
Figure 2.  The number and rate of clinical studies including biomarker assessments 
(source: analyzed based on data in ClinicalTrials.gov. See Appendix 1 for details.) 
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Figure 3.  Pharmacogenomic biomarker information in drug labeling (source: FDA, 
2014) 
1.2. Concept of personalized medicine 
Personalized medicine is a medical model that is aligned with the existing 
paradigm change. In the late 1990s, the term ‘personalized medicine’ was first 
introduced by Langreth and Waldholz (Jørgensen, 2009; Langreth and Waldholz, 
1999). Subsequently, scientific advantages have made it possible to diagnose and treat 
a rapidly growing number of diseases much earlier and with greater precision than ever 
before. These developments have vastly expanded physicians’ power to customize 
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therapy, maximizing drug treatment effectiveness and minimizing side effects (Aspinal 
and Hamermesh, 2007). 
Currently, personalized medicine is widely defined as a tailored approach to 
patient treatment, based on the molecular analysis of genes, proteins, and metabolites 
(Davis et al., 2009). It aims to achieve optimal medical outcomes by helping 
physicians and patients choose the disease management approaches likely to work best 
based on the detection of the patient’s unique genetic and environmental profile 
(Amir-Aslani and Mangematin, 2010; Marshall, 1998; McClellan et al., 2013; Ong et 
al., 2012; Tutton, 2012). 
In the field of pharmacotherapy, the techniques of utilizing a stratified approach 
and identifying groups of patients based on certain biologic characteristics or 
biomarkers, as detected by companion diagnostic (CoDx) tests, have the potential to be 
more efficient and effective than the traditional approaches, while reducing undesirable 
drug interactions and side effects (Figure 4). Recent advances in understanding of the 
disease pathophysiology, drug activity, and biomarkers involved in these approaches 
have resulted in a focus on tailoring treatment for specific patient subgroups based on 
their genetic makeup or other differentiating features (Desiere et al., 2013). 
In addition, this trend has led to a recent rise in academic and practitioner interest 
in personalized medicine development. As shown in Figure 5, the increase in the 
number of publications about personalized medicine has shown an exponential growth 
since the Langreth and Waldholz’s first article was published in 1999 (Jørgensen, 
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2011). The growth rate has been significant, especially within the past few years. 
Additional evidence of a growing interest in personalized medicine is detailed in Table 
1 (FDA, 2011; Moore et al., 2012; Personalized Medicine Coalition, 2006; 2011; 
PricewaterhouseCoopers, 2009; Tufts Center for the Study of Drug Development, 
2010; 2011). 
 
 
Figure 4.  Concept of personalized medicine (source: Haruya, original) 
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Figure 5.  Number of articles per year from 1999 to 2010 that included the term 
‘personalized medicine’ (source: Jørgensen, 2011) 
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Table 1.  Statistics demonstrating growing scientific, medical and economic interests 
in personalized medicine (source: Moore, 2012) 
Example Statistic 
Number of prominent examples of personalized medicine 
drugs, treatments and diagnostics products available in 2006 
13 
Number of prominent examples of personalized medicine 
drugs, treatments and diagnostics products available in 2011 
72 
Percentage of marketed drugs with a CoDx in 2011 1% 
Percentage of marketed drugs that inform or recommend 
genetic testing for optimal treatment 
10% 
Number of pharmacogenomic biomarkers that are included 
on US-FDA approved drug labels 
33 
Portion of all treatments in late clinical development that 
rely on biomarker data 
30% 
Portion of all treatments in early clinical development that 
rely on biomarker data 
50% 
Portion of all treatments in preclinical development that rely 
on biomarker data 
60% 
Amount of all biopharmaceutical companies surveyed that 
require all compounds in development to have a biomarker 
in 2011 
30% 
Percentage increase in personalized medicine investment by 
industry over the last 5 years 
75% 
Estimated personalized market size in 2009 
$225–232 
billion USD 
Estimated personalized market size in 2015 
$344–452 
billion USD 
Estimated molecular diagnostics market size in 2009 $3 billion USD 
Estimated molecular diagnostics market size in 2015 $7 billion USD 
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1.3. Opportunities in personalized medicine 
development 
1.3.1. Market trends in personalized medicine 
While still in the very early stages, personalized medicine is steadily emerging as 
the new healthcare paradigm (Figure 6). According to PricewaterhouseCoopers’ 
estimates, the total US market for personalized medicine was estimated at $232 billion 
USD in 2009 and is projected to grow 11% annually, nearly doubling in size by 2015 
to a total of $452 billion USD (PricewaterhouseCoopers, 2009). The core segment of 
this market, which is comprised primarily of diagnostic tests and targeted therapies, is 
estimated at $24 billion USD and is expected to grow by 10% annually to $42 billion 
USD by 2015. 
While the market for personalized medicine diagnostics and therapeutics shows 
great potential, the biggest opportunities exist beyond these core products and services, 
particularly in less traditional, more consumer-oriented areas. The nutrition and 
wellness market, including retail health, complementary and alternative medicine, 
nutraceuticals and organic care, and health clubs and spas, is estimated at $196 billion 
USD and projected to grow by 7% annually to $292 billion USD by 2015. The 
personalized medical care segment of the market, including telemedicine, electronic 
medical records, and disease management services, is estimated to be between $4 
billion USD and $12 billion USD and could grow tenfold to over $100 billion USD by 
2015. This segment largely consists of a range of healthcare players, as well as 
information technology companies that are starting to enter the space. 
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Such robust market size and growth potential will continue to attract many new 
players and require the development of new business models. Specifically, a wide 
variety of organizations that successfully market directly to consumers are entering this 
space, including consumer products, food and beverage, leisure and retail companies, 
as well as more traditional health companies. 
There are other products and services related to the field of personalized medicine, 
such as genetically modified food and stem cell products. The growth of these newly 
emerging submarkets is difficult to predict. 
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Figure 6.  Personalized medicine market size in 2009 and 2015 (source: PricewaterhouseCoopers, 2009) 
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1.3.2. Benefits of personalized medicine for each 
player 
The personalized medicine approach is clearly focused on patient benefits. 
However, there are other key stakeholders in the healthcare environment that may also 
benefit from the development and availability of personalized medicine, including 
physicians, regulatory agencies, pharmaceutical companies, diagnostic companies, 
society, and other healthcare providers (Aspinall et al., 2007; Blair, 2010; Desiere et al., 
2013; Love et al., 212; Parkinson and Ziegler, 2009). According to 
PricewaterhouseCoopers, key challenges, key opportunities, and key barriers for each 
player can be summarized as shown in Table 2 (PricewaterhouseCoopers, 2009). 
Since it can increase economic benefits, personalized medicine development 
would be especially important to pharmaceutical businesses (Figure 7) (Chugai 
Pharmaceutical, 2011). In particular, the largest economic benefit for pharmaceutical 
firms’ incorporation of personalized medicine may be decreased study periods and 
patient numbers in clinical studies. For instance, in the pivotal phase III study of 
Trastuzumab, patients with human epidermal growth factor receptor 2 (HER2)-positive 
tumours were eligible, and 469 patients were enrolled. However, if the study was not 
conducted with a preselection of patients with HER2 overexpression, a much larger 
trial (8050 patients may be needed if the sample size was calculated based on 
untargeted design) would have been needed in order to detect the same observed 
survival gain (Slamon et al., 2001; Winther and Jørgensen, 2010).  
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Table 2.  Key challenges, key opportunities, and key barriers in personalized medicine for each player (source: PricewaterhouseCooper, 
2009) 
Player Key Challenges Key Opportunities Key Barriers 
Pharmaceutical, 
biotechnology, and 
medical device 
companies 
 Moving from general to 
specific treatments, and 
from disease treatment to 
prevention 
 Reducing time, cost, size, 
and failure rate of clinical 
trials 
 Capitalizing on 
preferential use of and 
premium pricing for 
drugs of proven 
effectiveness 
 Reducing the number of 
drugs recalled as the 
result of safety concerns 
 Changing research funding models and 
drug approval regulations 
 Addressing pricing and reimbursement 
 Identifying appropriate incentives for 
innovation 
 Addressing changing revenue streams 
(i.e., shift from blockbuster model to 
smaller, targeted markets) 
 Navigating the cultural shift required to 
work with diagnostics companies to 
match drugs with CoDx 
 Developing the ability to share R&D 
information both internally and with 
external collaborators 
 Recognizing the need to share 
‘precompetitive data’ to avoid redundant 
research 
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Player Key Challenges Key Opportunities Key Barriers 
Diagnostic 
companies 
 Developing and 
validating new 
diagnostics to enable 
personalized medicine 
 Capitalizing on a growing 
market driven in part by 
new, value-based 
reimbursement policies 
 Creating new 
partnerships with 
pharmaceutical 
companies 
 Capitalizing on new 
distribution models to 
create new businesses 
 Addressing joint CoDx/drug approval 
processes/ regulations, including the 
daunting cost of traditional randomized 
controlled trials 
 Addressing pricing and reimbursement 
practices 
 Determining if, when, and how to 
partner with drug companies 
 Identifying and mobilizing resources 
needed to educate physicians about 
diagnostic tests 
 Developing improved decision support 
tools to assist physicians to take action 
based on test results 
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Player Key Challenges Key Opportunities Key Barriers 
Technology 
companies 
(including medical 
device 
manufacturers) 
 Developing new business 
models to capitalize on 
the value of data 
 Developing/embracing 
new technologies for 
measurement and 
visualization 
 Facilitating new, 
data-driven healthcare 
models 
 Facilitating new data 
mining models to make 
sense of vast quantities of 
data 
 Developing new product 
offerings 
 Creating new 
partnerships 
 Developing common data standards 
 Accelerating medicine/IT convergence 
 Understanding and influencing emerging 
regulatory standards 
 Protecting privacy and preventing 
genetic discrimination 
 Securing regulatory approval of 
combination devices 
 Overcoming a lack of domain 
knowledge of the healthcare space 
Other 
non-healthcare 
companies (e.g., 
consumer products, 
food, beauty/ 
cosmetics) 
 Adapting to a new focus 
on wellness and the rise 
of consumerism 
 Developing effective 
strategies to broaden the 
definition of what is 
considered ‘health’ 
 Addressing consumer 
demands for higher 
quality foods and 
products that contribute 
to healthfulness 
 Developing new products 
 Tapping new markets 
 Engaging in more precise 
customer segmentation 
 Educating the public about the multitude 
of available wellness options 
 Influencing and understanding emerging 
regulations 
 Developing better consumer metrics 
 Overcoming a lack of domain 
knowledge of the healthcare space 
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Player Key Challenges Key Opportunities Key Barriers 
Health systems, 
AMCs, and other 
providers 
 Providing cutting edge 
care while controlling 
healthcare delivery costs 
 Receiving reimbursement 
for providing wellness 
and prevention services 
 Operationalizing a 
consumer-oriented 
business model 
 Developing new models 
of care 
 Increasing revenues 
 Improving 
quality/outcomes 
 Adapting to the ‘unbundling’ of the 
hospital and non-traditional competitors 
 Making operational changes 
 Correcting misalignment of incentives 
 Managing consumer/patient expectations 
for costly and potentially unnecessary 
diagnostic tests 
Government and 
private payers 
 Embracing innovation 
 Controlling healthcare 
reimbursement costs 
while improving 
healthcare outcomes to 
increase value per dollar 
spent 
 Influencing new 
reimbursement models 
 Identifying risk more 
precisely while delivering 
improved quality 
 Realigning provider incentives 
 Collecting and disseminating outcome 
data 
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Figure 7.  Economical benefits of personalized medicine approach (source: modified 
based on Chugai Pharmaceutical’s presentation material, 2011) 
1.4. Personalized medicine development 
1.4.1. Regulatory requirements for CoDx 
In approaches to personalized medicine, CoDx have emerged as crucial tools for 
identifying patient sub-segments for drug treatment (Love et al., 2012; Papadopoulos 
et al., 2006; Singer and Watkins, 2012). 
There are several policy and guidance documents issued from the U.S. FDA (FDA, 
2013; Personalized Medicine Coalition, 2014) (Table 3). According to the recent 
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guidelines issued by the U.S. FDA, it specify that CoDx is essential for the safe and 
effective use of a corresponding therapeutic product to (i) identify patients most likely 
to benefit from the therapeutic product, (ii) identify patients likely to be at an increased 
risk of serious adverse reactions due to treatment with the therapeutic product, (iii) 
monitor treatment response to the therapeutic product for the purpose of adjusting 
treatment to achieve improved safety or effectiveness, and (iv) identify patients in the 
population for whom the therapeutic product has been adequately studied and found to 
be safe and effective (FDA, 2014). 
The U.S. FDA guidelines also specify that a therapeutic product and its 
corresponding CoDx should be developed contemporaneously, with the clinical 
performance and clinical significance of the CoDx established using data from the 
clinical development program of the corresponding therapeutic product (FDA, 2014).  
Particularly, according to the labeling regulations for drugs and biological 
products (FDA, 2014), product labeling must include information about: (i) specific 
tests necessary for selection or monitoring of patients who need a drug; (ii) dosage 
modifications for special patient populations (e.g., groups defined by genetic 
characteristics); and (iii) the identity of any laboratory test(s) helpful in following a 
patient’s response or in identifying possible adverse reactions. The labeling regulations 
identify sections where such discussion is appropriate (e.g., Indications and Usage, 
Dosage and Administration, Contraindications, Warnings and Precautions, Use in 
Specific Populations). In addition, labeling in vitro diagnostics (IVD) is also required 
to specify the intended use of the diagnostic device (FDA, 2014). Therefore, a CoDx 
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that is intended for use with a therapeutic product must specify the therapeutic 
product(s) for which it has been approved or cleared for use. 
 
Table 3.  Policy and guidance documents from the U.S. FDA (source: modified based 
on Personalized Medicine Coalition, 2014) 
Year Policy and guidance documents 
2005 
Guidance on PG Data Submissions Concept Paper on Drug-Diagnostic 
Co-Development 
2007 Guidance on Pharmacogenomic Tests and Genetic Tests for Heritable Markers 
2008 
E15 Definitions for Genomic Biomarkers, Pharmacogenomics, 
Pharmacogenetics, Genomic Data and Sample Coding Categories 
2010 Guidance on Qualification Process for Drug Development Tools 
2011 
E16 Guidance on Biomarkers Related to Drug or Biotechnology Product 
Development: Context, Structure, and Format of Qualification Submissions 
Guidance on in vitro Companion Diagnostic Devices 
2012 
Guidance on Clinical PG: Premarketing Evaluation in Early Phase Clinical 
Studies 
Guidance on Clinical Trial Designs Employing Enrichment Designs 
2013 
Guidance on Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase 
Clinical Studies and Recommendations for Labeling 
2014 
Guidance for industry and Food and Drug Administration staff – In vitro 
companion diagnostic devices. 
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1.4.2. Drug-CoDx combinations 
Based on this guidance issued by FDA (FDA, 2014), it is clear that drug-CoDx 
combinations would be one of the key components in personalized medicine 
development. The history of drug-diagnostic combinations was initiated with the 
discovery of the estrogen receptor (ER) in the late 1950s (Jensen et al., 1967). Soon 
after that discovery, a diagnostic assay for the detection of the receptor in tissue was 
developed in the beginning of the 1960s (Jensen et al., 1967; Winther and Jørgensen, 
2010). Subsequently, in the 1970s, a drug was developed by ICI Pharma (today 
AstraZeneca) for the treatment of breast cancer that was targeted towards ER. This 
drug was the selective ER modulator tamoxifen (Nolvadex
®
; AstraZeneca). Based on a 
phase II study of tamoxifen performed in patients with advanced breast cancer, the 
investigators concluded that there was a high correlation between treatment response to 
the drug and a positive test result from the ER assay, suggesting that the ER assay 
should be used for the selection of patients for treatment with tamoxifen (Lerner, 1976; 
Winther and Jørgensen, 2010). In fact, the ER assay is still a very important 
stratification test in breast cancer, and is used for selecting patients for treatment with 
tamoxifen or aromatase inhibitors, such as anastrozole (Arimidex
®
; AstraZeneca) and 
letrozole (Femara
®
; Novartis). 
Over the last decade, a number of drugs have been developed and marketed 
together with CoDx in order to identify the patients who are most likely to respond to 
therapy (Table 4) (FDA, 2014). One of the best-known examples is trastuzumab 
(Herceptin
®
; Roche/Genentech), the humanized monoclonal antibody directed towards 
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HER2 and its corresponding CoDx, the immunohistochemical (IHC) assay 
HercepTest
®
 (Dako). During clinical development, trastuzumab clearly showed an 
increase in the clinical benefit of first-line chemotherapy in metastatic breast cancer 
that overexpresses HER2. Furthermore, the use of the IHC assay for selecting 
HER2-positive breast cancer served as a major inspiration for the parallel drug-CoDx 
co-development model (Slamon et al., 2001; Jørgensen; 2012). 
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Table 4.  Examples of the U.S. FDA approved drugs that require CoDx (source: FDA, 2013) 
Drug Drug Manufactures CoDx CoDx Manufacturers 
Zelboraf Roche Cobas 4800 BRAF V600 Mutation Test Roche Diagnostics 
Tarceba Roche Cobas EGFR Mutation Test Roche Diagnostics 
Erbitux Bristol-Myers Squibb 
Dako EGFR PharmDx Kit Dako 
Therascreen KRAS RGQ PCR Kit Qiagen 
Vectibix Amgen 
Dako EGFR PharmDx Kit Dako 
Therascreen KRAS RGQ PCR Kit Qiagen 
Gleevec/Glivec Novartis DakoCytomation c-Kit PharmDx Dako 
Kadcyla Roche 
HER2 IQFISH PharmDx Dako 
HercepTest Dako 
Perjeta Roche 
HER2 IQFISH PharmDx Dako 
HercepTest Dako 
Gilotrif Boehringer Ingelheim Therascreen EGFR RGQ PCR Kit Qiagen 
Mekinist GlaxoSmithKline THxID BRAF Kit bioMérieux 
Tafinlar GlaxoSmithKline THxID BRAF Kit bioMérieux 
Xalkori Pfizer VYSIS ALK Break Apart FISH Probe Kit Abbott 
ALK: Anaplastic lymphoma kinase; BRAF: B rapidly accelerated fibrosarcoma; EGFR: Epidermal growth factor receptor; FISH: 
Fluorescence in situ hybridization; HER2: Human epidermal growth factor receptor 2; KRAS: Kirsten rat sarcoma 
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1.4.3. Drug-CoDx co-development 
Concomitant development of a drug and its CoDx is considered to be best practice, 
bringing the drug-CoDx combinations into the market (Figure 8). There are a number 
of articles describing the ideal process or way of collaborating between pharmaceutical 
and diagnostic companies for personalized medicine development (Cheng et al., 2012; 
Desiere et al., 2013; Jørgensen, 2012; Metcalfe, 2010; Moore et al., 2012; Scherf et al., 
2010; Simon, 2013; PricewaterhouseCoopers, 2011; Winther and Jørgensen, 2010). 
For instance, Jørgensen (2012) suggested that collaborations between 
pharmaceutical and diagnostics companies for CoDxD begin from an early stage of 
drug development. Ideally, as the clinical efficacy data generated during phase II must 
be used to provide an indication of the predictive or selective value of the assay, a 
CoDx assay should be developed during the preclinical development of the drug, or at 
least at the beginning of phase I (Jørgensen, 2012). 
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Figure 8.  Ideal drug-CoDx co-development process (source: Scherf et al., 2010)
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In contrast, according to Simon, the ideal approach to co-development of a drug 
and CoDx involves three key points (Simon, 2013). First, there is the identification of a 
predictive biomarker based on an understanding of the mechanism of action of the 
drug and the role of the drug target in the disease pathophysiology. This biological 
understanding should be validated and refined during pre-clinical studies and early 
phase clinical stages. Second, it is necessary to develop an analytically validated test 
for measurement of that biomarker. In this case, analytically validated means that the 
test accurately measures what it is supposed to measure, or if there is no gold-standard 
measurement, that the test is reproducible and robust. Third, there is the use of that test 
to design and analyze a new clinical trial to evaluate the effectiveness of the drug and 
how effectiveness relates to the biomarker value. 
Furthermore, Winther and Jørgensen (2010) emphasized that clinical study design 
should be an essential point when considering drug-CoDx co-development (Winther 
and Jørgensen, 2010). The randomized clinical study has been a crucial factor 
regarding the change in pharmacotherapy from being more or less empirical to the 
contemporary substantially more evidence-based approach. For most drugs developed 
during the last several decades, the standard for documenting safety and efficacy and 
obtaining regulatory approval has been that at least two independent, randomized, 
phase III studies show positive results above the current standard treatment. However, 
despite this approach being a kind of ‘gold standard’ in drug development, the design 
of the traditional randomized clinical study does not answer the question of the 
response to a given drug in the individual patient. Thus, extrapolation of the average 
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study result from the entire patient population could produce negative results (Winther 
and Jørgensen, 2010; Woodcock, 2007). 
With the emergence of new molecular targeted drugs, especially within oncology, 
it is important to address variability in individual pathophysiology in the drug 
development process in order to draw the correct conclusions. This can only be 
accomplished by incorporating molecular diagnostic methods into clinical trial designs. 
As proposed in the parallel drug-CoDx co-development model, by making CoDx an 
integrated part of the clinical development process, important information about the 
molecular pathophysiology will be accessible, and this information should be used to 
identify patients likely to respond to the targeted drugs tested in clinical trials (Winther 
and Jørgensen, 2010). 
 
1.4.4. Details of CoDx development process 
The aim of CoDx is to measure if a patient is likely to positively respond to a 
specific drug in a reliable and robust setting (FDA, 2014). Hence, the development of 
CoDx is dependent on the selection of a relevant and valid biomarker as well as patient 
outcome data that reflect the efficacy of the medical drug (Papadopoulos et al., 2006; 
Phillips et al., 2006; Scherf et al., 2010; Metcalfe, 2010). 
Figure 9 shows the stages of CoDx development that correspond to the clinical 
phases of drug development (FDA, 2005; Jørgensen, 2012; Metcalfe, 2010; Scherf et 
al., 2010; Winther and Jørgensen, 2010). Taken together, this process demonstrates the 
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need for close collaboration between pharmaceutical and diagnostic organizations to 
simultaneously develop drugs and CoDx. In this thesis, the processes of drug and 
CoDx development are defined including the steps indicated in Figure 9. Regarding 
CoDx development, diagnostic firms need to follow the steps described below. 
 
 
Figure 9.  Process for drug-CoDx co-development (source: Winther and Jørgensen, 
2010) 
 
Feasibility studies are the first step in the CoDx development process and suggest 
whether or not CoDx development is possible (Phillips et al., 2006; Scherf et al., 2010; 
Winther and Jørgensen, 2010). This stage also explores the biomarker to be used in the 
CoDx. The biomarker is a characteristic that measures and evaluates normal biological 
processes, disease processes, or responses to a therapeutic intervention. As such, 
biomarkers are applied to identify patients most likely to benefit or to experience an 
increased risk from a potent drug. After biomarkers are selected for a potent drug, an 
appropriate platform will also be selected for biomarker detection. Many platforms are 
currently available for biomarker detection (Table 5), and selecting the correct one(s) 
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is crucial to the successful CoDx and drug development (Love et al., 2012). Significant 
factors for the selection of an appropriate assay platform include the biomarker type 
(e.g., genetic, genomic, protein), sample type (e.g., serum, tissue-based, urine), where 
the test will be used (e.g., point-of-care test or a test performed by a specialist 
laboratory), how to achieve the highest level of reliability, and the test’s required 
sensitivity and specificity of (Desiere et al., 2013; Papadopoulos et al., 2006). The 
wrong platform can potentially be detrimental to patient care and an obstacle to the 
successful uptake of the diagnostic test and the drug. 
Further, a feasibility assay/kit system is developed as a prototype. During this 
stage, activities related to the design of assay specifications are typically performed, 
including definitions of assay sensitivity, specificity, interpretation system, and clinical 
indications. CoDx exploratory clinical trial testing provides information concerning 
assay performance in the clinical setting and the correlation between patient response 
and assay results (Winther and Jørgensen, 2010). 
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Table 5.  Examples of biomarkers, platforms/technologies, and CoDx (source: Fridlyand et al., 2013) 
Biomarker 
Platform or 
technology 
Examples of CoDx Challenges 
Mutation(s) Sequencing No current examples 
Test results depend on the percentage of cells with 
mutations (i.e., there is a lower detection limit); may 
measure non-specific exons 
Mutation(s) qPCR 
Cobas 4800 BRAF V600 
Mutation Test 
Test results depend on the percentage of mutant 
sequences, adequate specimen integrity, and sufficient 
DNA detection 
Protein expression 
Immunohistochemistry 
staining 
Dako HercepTest 
Generally, semi-quantitative and non-automated 
evaluation; test results can depend on pre-analytical 
tissue processing factors 
Gene expression 
Quantitative real-time 
PCR 
No current examples 
Manual macrodissection may be necessary for samples 
with low tumor cell content 
DNA copy number 
FISH or chromogenic 
in situ hybridization 
HER2 FISH pharmDx Kit 
Relatively complex assay technology and 
interpretation 
Fusion protein 
product 
FISH 
Vysis ALK Break Apart 
FISH Probe Kit 
Relatively complex assay technology and 
interpretation 
Gene signature 
Next-generation 
sequencing 
No current examples Complex assay technology and interpretation 
ALK: Anaplastic lymphoma kinase; BRAF: B rapidly accelerated fibrosarcoma; FISH: Fluorescence in situ hybridization; HER2: 
Human epidermal growth factor receptor 2; NGS: Next-generation sequencing 
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In the next stage, the prototype assay is refined to comply with design 
specifications and to demonstrate analytical validation. Once the biomarker in question 
has been adequately de-risked through the qualification process, it can be developed on 
a commercial IVD platform. The costs per marker of this step are usually high in 
relation to the development of the prototype and this development work will not be 
undertaken unless there is a high likelihood that the resulting novel IVD assay will 
attain regulatory approval and demonstrate sufficient clinical utility to warrant broad 
commercial uptake (Metcalfe, 2010). During this stage, areas of focus include 
preparation of assay control material and final optimization and characterization of the 
full assay. Verification studies of the assay include testing of: accuracy; sensitivity; 
specificity; robustness (tolerance); precision (intra-assay run, inter-assay run, inter-lot 
variability, inter-reader variability, inter-instrumentation variability, and 
inter-laboratory variability); and reproducibility (internal and external evaluation) 
(Jørgensen, 2012; Metcalfe, 2010; Scherf et al., 2010; Winther and Jørgensen, 2010). 
Finally, clinical validation and utility are confirmed by demonstrating how the test 
information facilitates superior decision-making relating to the treatment. Typically, 
this is accomplished by further refinement of the patient’s condition/disease 
characterization beyond that possible using the current standard of care (Rifai et al., 
2006; Simon, 2013; Winther and Jørgensen, 2010). 
This process is completed by the submission of all requested data to the relevant 
regulatory authorities, concurrent with the drug regulatory submission. Following 
regulatory approval, the assay becomes the commercialized CoDx product containing 
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all reagents, including positive and negative control materials (if required), and 
pre-diluted analytes (e.g., antibody/probe). 
1.5. Partnerships in Drug-CoDx co-development 
Outsourcing options for pharmaceutical companies are widely available and 
commonly utilized in the traditional drug development and approval process (Moore, 
2012). One of the common choices is contract research organizations (CROs), which 
provide efficient, cost-effective solutions to conducting clinical research. Specifically, 
CROs can offer assistance with drug development, preclinical research, clinical 
research, and clinical trial management. In addition, their focus and expertise is on 
operational efficiency and clinical trial support for pharmaceuticals. Thus, CROs offer 
a complete solution for large drug companies developing traditional therapeutics. 
However, in drug-CoDx co-development, to develop a CoDx for their own 
product, pharmaceutical companies must find a diagnostic partner that specializes in 
the development and manufacturing of diagnostic tests and equipment. There are two 
options for pharmaceutical companies to access to CoDx co-development: external 
partnerships or in-house cooperation (Figure 10) (PricewaterhouseCoopers, 2009, 
2011). 
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Since most companies do not have sufficient in-house CoDx development 
capability, external partnerships are the main route used by pharmaceutical firms, and 
include licensing-in and fee-for-service collaboration. Indeed, the rising numbers of 
CoDx partnerships between pharmaceutical and diagnostic companies during 2009–
2010 imply that a larger number of pharmaceutical companies are seriously 
considering the need for biomarker and diagnostic programs to accompany their drug 
development efforts (Figure 11). 
In contrast, in-house cooperation tends only be available to pharmaceutical 
companies with both a pharmaceutical and an in vitro diagnostics (IVD) development 
organization. 
 
 
Figure 10.  Options for pharmaceutical firms to access CoDx co-development: 
In-house cooperation or external partnerships (source: Haruya, original) 
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Figure 11.  Number of CoDx partnerships between pharmaceutical and diagnostic 
companies (source: PricewaterhouseCoopers, 2011) 
1.6. Arguments on the way of collaboration for 
drug-CoDx co-development 
There are some previous studies that argued the way of collaboration for 
drug-CoDx co-development. For instance, Moore et al. (2012) indicated that there are 
several potential barriers to the current co-development process: a relatively low 
probability of success after a scientific discovery, navigating various development 
objectives for different drugs, targeting appropriate markets and users, lack of clear 
regulatory and policy guidance, and partnership challenges between research and 
diagnostic cultures (Moore et al., 2012). Consequently, they pointed out that there 
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should be as few partners as possible in the co-development process to avoid conflict 
and inefficiency. Therefore, from a pharmaceutical firm’s point of view, using 
in-house cooperation to co-develop the drug and its CoDx could be considered as a 
better option than partnerships with external diagnostic firms. 
The case of vemurafenib (Zelboraf
TM
) and its CoDx (Cobas
®
 4800 BRAF V600 
mutation test) is one example of in-house cooperation. The Cobas
®
 4800 BRAF V600 
mutation test is an IVD device developed by Roche Diagnostics as a CoDx to select 
melanoma patients with tumors carrying the B rapidly accelerated fibrosarcoma 
(BRAF) V600E mutation and who are treated with vemurafenib. Vemurafenib is a 
first-class selective inhibitor of oncogenic BRAF kinase, identified by Plexxikon and 
developed by Roche (Cheng et al., 2012; Roche Molecular Systems, 2011). In this case, 
Cheng et al. (2012) pointed out that the key success factors in the development process 
for vemurafenib were early identification of the BRAF V600E biomarker, early 
development of the diagnostic test, and close collaboration between the pharmaceutical 
and diagnostic development teams (Cheng et al., 2012). This focused and integrated 
process resulted in the first personalized medicine for the treatment of metastatic 
melanoma less than five years after the Investigational New Drug (IND) Application, a 
remarkably short time (Cheng et al., 2012; Roche, 2011). 
A contrasting case is that of crizotinib (Xalkori
®
) and its CoDx (VYSIS
®
 ALK 
Break Apart FISH Probe Kit), where co-development occurred through a partnership 
between Pfizer and Abbott Laboratories. VYSIS
®
 ALK Break Apart FISH Probe Kit is 
an IVD device developed by Abbott Laboratories to select non-small-cell lung cancer 
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(NSCLC) patients containing Anaplastic lymphoma kinase (ALK) rearrangements for 
treatment with crizotinib, which is an ALK inhibitor developed by Pfizer (Choi et al., 
2010; Gerber et al., 2010; Kwak et al., 2010). According to interviews with executives 
at Pfizer and Abbott Laboratories, it seems that some strategic problems arose during 
this co-development (Rockoff, 2011). Specifically, early on, Pfizer researchers 
hesitated to give Abbott Laboratories some of its valuable tumor tissue with the ALK 
genetic abnormality, while Pfizer fretted that Abbott Laboratories did not appear to 
update them on test development progress. 
Based on the above observations, having a diagnostics organization within one 
corporate group seems to be an advantage for effective drug-CoDx co-development 
because it can remove potential some issues around sharing the overall value of the 
drug-diagnostic combination and synchronization. 
However, as suggested by the disclosed CoDx development relevant deals, even in 
the case of pharmaceutical companies with internal diagnostic organizations, the route 
to access CoDx co-development has not been exclusively internal 
(PricewaterhouseCoopers, 2009, 2011). That is, regardless of whether or not a 
pharmaceutical firm has an internal IVD organization, it recently appears that a rising 
number of CoDx partnerships between pharmaceutical and diagnostics companies have 
been established (PricewaterhouseCoopers, 2009, 2011). This implies that having 
strong capability to build external partnerships would be more important for effective 
drug-CoDx co-development. 
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1.7. Corporate capability in personalized 
medicine development 
There are a number of articles that describe the ideal process or way 
pharmaceutical and diagnostic companies collaborate for personalized medicine 
development (Cheng et al., 2012; Desiere et al., 2013; Jørgensen, 2012; Metcalfe, 
2010; Moore et al., 2012; Scherf et al., 2010; Simon, 2013; PricewaterhouseCoopers, 
2011; Winther and Jørgensen, 2010). The major topic in these articles can be 
categorized as the process-orientation approach, which consists of structuring 
management according to the flow of organizational activities (Walter and Götze, 
2009). 
The implementation of process-oriented concepts is associated with productivity 
gains in organizations, and many academic and consulting publications have explained 
how different approaches provide improvements, primarily in terms of costs, quality 
and lead-time levels (Walter and Götze, 2009). In addition, these concepts have largely 
been implemented at operational levels, and ‘process improvement’ and ‘process 
reengineering’ could be considered the main approaches to this topic (Davenport, 
1993; Hammer and Champy, 1993; Harrington, 1991). While the importance of these 
optimizations cannot be denied, it should be recognized that they are fundamentally 
related to tactical and operational management aspects. 
In order to precisely understand strategic management, it is necessary to clarify 
corporate capability. However, to our knowledge, no study has clearly defined the 
level of personalized medicine development capability pharmaceutical and diagnostic 
Corporate Capability for Personalized Medicine Development 
The University of Tokyo, Mei Haruya 
38 
firms should have or how it can be managed in business practice. Additionally, since 
there has been a paradigm change from traditional drug development to personalized 
medicine, this is especially important in the pharmaceutical and diagnostic industries. 
Therefore, when analyzing the corporate capability of personalized medicine 
development in the pharmaceutical and diagnostic industries, it would be important to 
clarify differences in corporate capability between personalized medicine development 
and traditional drug development and to illustrate the corporate capability of mutual 
interactions between pharmaceutical and diagnostic companies. 
In order to define and illustrate such corporate capability of personalized medicine 
development, in next chapter, a literature review will be conducted to better understand 
the preceding discussion of corporate capability in product development. 
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Chapter 2: Literature Review 
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2.1. Process and corporate capability 
Process is usually defined in the context of an ‘input-output’ transformation 
(Harrington, 1991). Thus, a process might be considered an ‘action’ performed using 
resources and capabilities (Amit and Schoemarker, 1993). Such an action is the result 
of some skill the firm possesses. Therefore, a process may be seen as the application of 
a capability. 
In contrast, to be capable of some thing is to have a reliable capacity to bring that 
thing about as a result of intended action (Dosi et al., 2000). Capabilities fill the gap 
between intention and outcome, in such a way that the outcome bears a definite 
resemblance to what was intended. Within the literature, a general equivalence 
between ‘competency’ and ‘capability’ is often assumed (Dosi et al., 2000; 2008; 
Teece et al., 1997; Trejo et al., 2002; Ulrich and Smallwood, 2006; Vincent, 2008). 
Dosi et al. (2000) indicated that ‘capability’ should be a quite large-scale unit of 
analysis that has a recognizable purpose expressed in terms of the significant outcomes 
it is supposed to enable. Furthermore, it is significantly shaped by conscious decisions 
both in its development and deployment (Dosi et al., 2000). 
Based on this background, Walter and Götze (2009) proposed two assumptions: (i) 
a process represents the ordered application of resources and capabilities to provide 
some expected result (i.e., a process is a transformation performed using specific 
resources and capabilities), and (ii) each process can be performed because there is a 
corresponding ‘process-related’ capability that coordinates and applies the concerning 
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resources and other skills. Thus, this means that a process-related capability is the 
ability to execute a given process and can be understood as the capability of a business 
unit to execute a given process. The same logic should also be applied at the different 
process sublevels (i.e., sub-process, activity, and task) (Harrington, 1991). In each 
sublevel, other resources and capabilities are usually necessary to support the 
coordination of the subsequent lower process levels (Figure 12). 
Moreover, in order to manage the integrated use of the process-related capabilities, 
Walter and Götze (2009) also defined ‘main’ and ‘combined capabilities,’ which are 
capabilities related to the integration and application of bundles of combined and 
process-related capabilities, respectively. Based on this foundation, Figure 13 shows 
the net of relationships among different classes of capabilities whereby a core 
competence involves the integration of different capabilities that: (i) are located at 
different business units, and (ii) may be of any class (process-related, combined, and/or 
main). In the case of the represented core competence, one main and three combined 
capabilities integrate specific bundles of process-related capabilities. 
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Figure 12.  Framework of association between capabilities and processes (source: Walter and Götze, 2009) 
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Figure 13.  Net of relationships among corporate capabilities (source: Walter and 
Götze, 2009) 
 
Firms are heterogeneous in that they develop different organizational routines, 
even if they belong to the same industry and produce similar outputs. These features 
distinguish ‘capability’ from ‘organizational routines,’ as the latter term is used in 
organizational theory and evolutionary economics (Dosi et al., 2008). Firm-specific 
operations are based on organizational capabilities that have gradually been 
accumulated and shaped within firms (Dosi et al., 2000). Therefore, to precisely 
understand strategic management, it is important to clarify not only process but also 
process-related capability. Hence, in this thesis, corporate capability is defined as 
organizational process-related capability that enable firms to effectively deal with 
organizational problems in a firm-specific way; I aim to understand the corporate 
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capability of personalized medicine development from the perspective of both 
pharmaceutical and diagnostic firms. 
Thus, to prepare for illustration of these capabilities, a literature review is 
conducted in Chapter 2 to facilitate an understanding of current research trends in 
corporate capability. 
2.2. Corporate capability for new product 
development in pharmaceutical firms 
Corporate capability of new product development (NPD capability) is a key 
strategic activity in many firms because new products significantly contribute to sales. 
Some published articles have described measures for NPD capability in the 
pharmaceutical industry (Bierly and Chakrabarti, 1996; Deeds et al., 2000). 
Deeds et al. (1999) developed a model of new product development, which was 
tested on a sample of 94 pharmaceutical biotechnology companies (Deeds et al., 2000). 
In this study, it was hypothesized that NPD capabilities are a function of a firm’s 
scientific, technological, and managerial skills. To test this relationship, they 
developed several firm-specific measures in an attempt to triangulate the core construct 
of firm-specific NPD capabilities. 
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This study’s results have some important implications for entrepreneurs/managers 
of high technology firms. First, entrepreneur/managers need to view the choice of 
geographic location as an important strategic decision that will influence their firm’s 
access to the skilled technical personnel and knowledge streams. Furthermore, results 
indicate that choice locations have a significant concentration of similar firms, but the 
level has not yet reached a point where competition for resources in the local 
environment offsets any location advantages. In the case of biotechnology, this appears 
to indicate that prime locations would be expanding areas such as San Diego, Seattle, 
and Philadelphia rather than the established locations of Silicon Valley and Boston. 
Second, as scientific knowledge plays an increasingly important role in a firm’s 
success, the quality of the firm’s scientific team is a critical ingredient in new product 
development capability. However, regarding how to evaluate the quality of scientific 
personnel, results indicate that there is a strong positive relationship between the 
impact (as measured by citations) of a team’s prior research in the academic 
community and the productivity of that team in a commercial research laboratory. 
Therefore, the judgment of a scientific field, captured by citations or perhaps expert 
judgment, should prove to be a useful tool when evaluating personnel for a firm’s 
research team. 
Third, the study presented interesting results in its measurement of CEO 
experience and the percentage of members of the top management team with a Ph.D. 
As expected, a CEO’s prior experience in managing a commercial research facility 
enhances a firm’s new product development capabilities. However, results for the top 
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management team variable appear to indicate that overreliance on technical personnel 
in organization management detracts from the product development process. Taken 
together, these results seem to imply that while it is important that organization 
leadership has knowledge of and experience in managing the new product 
development process, it may be counterproductive to divert the energies of the firm’s 
scientific personnel away from the laboratory and into organization management. 
Therefore, a high technology venture appears to require leadership that understands 
and has experience in the new product development process, but is separate and 
distinct from the scientific team. This type of leadership keeps the scientific team 
focused on research and development, and out of the boardroom. 
In another study, Bierly and Chakrabarti (1996) aimed to better understand 
strategic management using the dynamic capabilities approach (Bierly and Chakrabarti, 
1996). In this study, they focused on two fundamental constructs of dynamic 
capabilities, technological learning and strategic flexibility, and discerned their 
influence on organizational performance. 
The researchers’ main argument was that a firm’s strategic flexibility moderates 
the relationship between technological learning and technological performance as 
evidenced by new product development. Consequently, their model is based on the 
synthesis of the traditions of research in strategic and technology management. 
Technological learning has been defined in two dimensions: internal and external 
learning. Additionally, strategic flexibility has been operationalized in financial, 
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marketing, manufacturing, and technological dimensions. In this study, data from the 
U.S. ethical pharmaceutical industry from 1977–1991 were used to test the hypotheses. 
Although the researchers found support for their basic argument, they observed 
that the strategic flexibility factors (i.e., Technological learning, strategic flexibility, 
and new product development) are related with the variables (i.e., research and 
development commitment, number of patents, measure of ‘scientific linkage’, and 
number of strategic alliances) in a more complex way. Furthermore, internal learning 
involves a different process than learning from external sources. Overall, the 
robustness of these findings is due to the longitudinal data and objective indicators 
used in construct measurement. 
2.3. Corporate capability for knowledge 
management in pharmaceutical firms 
Many articles describe corporate capability of knowledge management by dividing 
knowledge management into knowledge exploration and knowledge exploitation 
(Gilsing and Nooteboom, 2006; He and Wong, 2004; Kane and Alavi, 2007; Lavie and 
Rosenkopf, 2006; Lichtenthaler and Lichtenthaler, 2009; March, 1991). For instance, 
March (1991) indicated that exploration includes terms such as search, variation, risk 
taking, experimentation, play, flexibility, discovery, and innovation. Subsequently, 
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exploitation includes concepts such as refinement, choice, production, efficiency, 
selection, implementation, and execution (March, 1991). 
In addition, a substantial number of articles have argued about pharmaceutical 
firms’ capability of knowledge management by dividing internal and external 
knowledge sources (Bierly and Chakrabarti, 1996; Coates and Bals, 213; Graves and 
Langowits, 1993; Hoang and Rotharmel, 2010; Hughes and Wareham, 2010; 
Holmqvist, 2004). 
Hoang and Rothaermel (2010) distinguished the external and internal experiences 
of both exploration and exploitation (Hoang and Rothaermel, 2010). Specifically, they 
hypothesized that alliance exploitation experience has positive effects on research and 
development (R&D) project performance, while alliance exploration experience has 
negative effects. They further posited that an internal exploration competence allows 
firms to more fully leverage their external exploitation experience. In contrast, when 
firms combine internal exploitation experience with external exploration experience, 
the negative effects on R&D project performance become more pronounced. To test 
this integrative model of organizational learning, the researchers leveraged a unique 
and detailed dataset of 412 R&D biotechnology projects conducted by pharmaceutical 
companies between 1980 and 2000. Using a competing risk event-history model 
predicting successful product approval versus project termination, the researchers 
found that the combination of internal exploration and external exploitation improves 
R&D outcomes in the pharmaceutical industry, while the combination of internal 
exploitation and external exploration reduces R&D project performance. 
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In addition, Bierly and Chakrabarti (1996) conducted a study to identify groups of 
pharmaceutical firms with similar generic knowledge strategies, determine how these 
strategies change over time, and compare the groups’ profit margins (Bierly and 
Chakrabarti, 1996). In this study, the knowledge strategies of 21 U.S. pharmaceutical 
firms were analyzed from 1977 to 1991. Cluster analysis was used to group firms over 
different time periods based on: (i) balance between internal and external learning, (ii) 
preference for radical or incremental learning, (iii) learning speed, and (iv) breadth of 
knowledge base. In terms of results, the researchers found that there are four generic 
knowledge strategy groups: ‘Explorers,’ ‘Exploiters,’ ‘Loners,’ and ‘Innovators.’ 
Subsequently, they reported that the firms in the ‘Innovator’ and ‘Explorer’ groups 
tended to be more profitable than firms in the ‘Exploiter’ and ‘Loner’ groups. 
2.4. Architecture of product and development 
process for drug 
Some previous studies described knowledge management of product development 
by considering product architecture (Clark and Baldwin, 1994; Baldwin and Clark 
2000; Pisano, 2006; Ulrich, 1995). 
According to Baldwin and Clark’s definition, when a product or development 
process has ‘modularity,’ the elements of its design can be split up and assigned to 
modules according to a formal architecture or plan (Baldwin and Clark, 2000). For 
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instance, in the computer industry, firms do not design or make whole computer 
systems; instead, they design and/or make modules that are parts of larger systems. 
These modules include hardware components such as computers, microprocessors, and 
disk drives; software components such as operating systems and application programs; 
and process components such as fabrication, assembly, systems integration, and 
testing. 
In contrast, according to Pisano (2006), there are three points where 
pharmaceutical development differs from other high-tech sectors: (i) profound and 
persistent uncertainty, rooted in the limited knowledge of human biological systems 
and processes, makes drug development highly risky; (ii) the drug development 
process cannot be neatly broken into pieces, meaning that the multiple disciplines 
involved must work in an integrated fashion; and (iii) substantial knowledge from 
diverse disciplines comprise the pharmaceutical sector is intuitive or tacit, rendering 
the task of harnessing collective learning especially daunting (Pisano, 2006). 
Particularly, Pisano pointed out that effectively discovering and developing drugs 
requires all the pieces to come together and that the drug development process and 
drug product itself lack ‘modularity’ (Pisano, 2006). Consequently, it was indicated 
that integration across diverse scientific, technical, and functional domains is essential 
for discovering and developing drugs. 
It is clear that drug products themselves lack modularity. However, given the 
number of partnerships in the personalized medicine era, I argue that the process of 
drug development should have modularity. This could be one point Pisano did not 
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discuss; therefore, more research efforts need to be devoted to clarifying this when 
discussing corporate capability of personalized medicine development. 
2.5. Architecture of product and development 
process for CoDx 
Rajan et al. (2011) indicated that there are three key components that companies 
must address to successfully develop a CoDx: biomarkers that are predictive of a 
therapeutic response; accurate, cost-effective techniques for detecting biomarkers; and 
suitability of testing materials (Rajan et al., 2011). These three key components will be 
integrated to build commercialized CoDx product, which implies that CoDx 
knowledge should be viewed as integrated knowledge consisting of multiple key 
knowledge elements. Rajan et al. also pointed out that the adoption and commercial 
success of a CoDx technology require: flexibility in handling clinically relevant body 
fluids and tissue biopsy samples; cost-effectiveness and scalability in relation to 
clinical demand; accuracy, reliability and efficient turnaround time; and the ability to 
multiplex efficiently in light of patient-to-patient heterogeneity and the limited utility 
of single biomarkers (Rajan et al., 2011). With this background, they concluded that to 
create an effective CoDx, one of the most important things diagnostic companies need 
to do is carefully select technologies based on the characteristics of the particular 
biomarker and on how the diagnostic will be used. To ensure routine, widespread 
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adoption, Rajan et al. emphasized that diagnostic companies must thoroughly evaluate 
the pros and cons of the technology and ensure that the key factors of accuracy, 
reliability, cost effectiveness, turnaround time, and scalability are consistent with 
clinical demand (Appendix 2). 
In contrast, most CoDx products consist of medical devices (including necessary 
software) and diagnostic kits (Rajan et al., 2011). Therefore, the architecture for both 
the product itself and its development process should be completely different from that 
for drug products and their development process. Consequently, this signifies that 
corporate capability for CoDx development should be illustrated separately from that 
of drug development. However, although some studies describe the CoDx development 
process (FDA, 2005; Jørgensen, 2012; Metcalfe, 2010; Scherf et al., 2010; Winther 
and Jørgensen, 2010), thus far, there is no study that define or illustrate diagnostic 
firms’ corporate capability for CoDx or traditional diagnostics development. 
2.6. Research questions 
As mentioned in Chapter 1, a number of articles describe the ideal process or 
collaboration between pharmaceutical and diagnostic companies for personalized 
medicine development (Cheng et al., 2012; Desiere et al., 2013; Jørgensen, 2012; 
Metcalfe, 2010; Moore et al., 2012; Scherf et al., 2010; Simon, 2013; 
PricewaterhouseCoopers, 2011; Winther and Jørgensen, 2010). 
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For instance, Moore et al. (2012) reported several potential barriers to the current 
co-development process including: a relatively low probability of success after a 
scientific discovery, navigating various development objectives for different drugs; 
targeting appropriate markets and users, a lack of clear regulatory and policy guidance, 
and partnership challenges between research and diagnostic cultures. Moreover, they 
indicated that there should be as few partners as possible in the drug-CoDx 
co-development process to avoid product delays and inefficiency. In addition, 
Jørgensen (2012) suggested that collaborations between pharmaceutical and 
diagnostics companies for drug-CoDx co-development begin in an early stage of drug 
development. Ideally, a CoDx assay should be developed during preclinical drug 
development (or at least the beginning of phase I) because the clinical efficacy data 
generated during phase II must be used to provide an indication of the predictive or 
selective value of the assay (Jørgensen, 2012). 
Pertaining to the pharmaceutical industry, these relevant previous works provided 
some particularly useful insight into drug-CoDx co-development. However, all 
conclusions reached in these studies were based on qualitative analysis of case studies, 
while no data from a quantitative study was utilized in reporting results. Moreover, all 
previous discussions focused on process and no study clearly defined or illustrated 
corporate capability for personalized medicine development. 
In contrast, as reviewed in Chapter 2, there are a number of articles describing the 
corporate capability of traditional drug development using statistical procedures 
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(Bierly and Chakrabarti, 1996; Deeds et al., 2000; Graves and Langowits, 1993; Hoang 
and Rotharmel, 2010)  
For example, Deeds et al. (1999) suggested that NPD capability can be measured 
by a firm’s location, scientific capabilities, external contacts, and the functional and 
educational backgrounds of top managers (Deeds et al., 2000). Additionally, Hoang 
and Rothaermel (2010) distinguished between external and internal experiences of both 
exploration and exploitation. Here, it was found that the combination of internal 
exploration and external exploitation improves R&D outcomes, while the combination 
of internal exploitation and external exploration reduces R&D project performance 
(Hoang and Rothaermel, 2010). 
However, there is one major difference between development of personalized 
medicine and traditional drugs. In particular, this is the ‘synchronized’ co-development 
of two products. In other words, traditional drug development only requires the 
development of one product (i.e., a drug), while personalized medicine development 
requires that development of both a drug and CoDx. Moreover, in order to gain 
regulatory approval at the same time, it is necessary for the two products to be 
developed simultaneously, through very close collaboration between pharmaceutical 
companies and their diagnostic partners. Therefore, it is not appropriate to simply 
apply the results obtained from previous studies to personalized medicine 
development. 
Corporate Capability for Personalized Medicine Development 
The University of Tokyo, Mei Haruya 
55 
Congruent with this situation, the first research question raised in this thesis is as 
follows: What are the key factors and how do these key factors affect corporate 
capability of personalized medicine development in pharmaceutical firms? 
As described above, a number of previous studies describe corporate capability of 
new product development or knowledge management for drug development. However, 
while some studies describe the CoDx development process (FDA, 2005; Jørgensen, 
2012; Metcalfe, 2010; Scherf et al., 2010; Winther and Jørgensen, 2010), no study thus 
far that describes diagnostic firms’ corporate capability of CoDx development. It is 
obvious that an understanding of diagnostic firms’ capability for developing CoDx is 
essential when considering the corporate capability of personalized medicine 
development. 
Therefore, to clarify this point, the second research question raised is as follows: 
What types of knowledge sources exist, and what corporate capability is required for 
diagnostic firms to manage these sources and interact with their stakeholders for 
CoDx development? 
2.7. Thesis objectives 
With these two research questions in mind, this thesis conducted two studies to 
further understand corporate capability (i.e., organizational capabilities that enable 
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firms to effectively deal with organizational problems in a firm-specific way), of 
personalized medicine development from pharmaceutical and diagnostic firms’ points 
of view, respectively (Figure 14). The outline for the thesis is provided below. 
First, in Chapter 3, quantitative analysis was conducted to illustrate the corporate 
capability of personalized medicine development in the pharmaceutical industry (PMD 
capability). In this analysis, the first step is to define three factors that illustrate PMD 
capability. Second, several hypotheses are formulated and observed variables are 
collected to develop a research model called the PMD capability model. Finally, in 
order to validate the research model, empirical analysis is conducted using structural 
equation modeling (SEM). 
Next, in Chapter 4, a framework was developed to illustrate diagnostic firms’ 
corporate knowledge sourcing and management capability of CoDx development. First, 
three key knowledge elements necessary for CoDx development are defined. Second, a 
unique framework is constructed to detail firms’ ability to manage this knowledge. 
Finally, the proposed framework is applied to several CoDx development cases to test 
its practical utility. 
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Figure 14.  Scope of this thesis (source: Haruya, original) 
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Chapter 3: Corporate Capability of 
Personalized Medicine Development 
in the Pharmaceutical Industry 
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3.1. Introduction 
Despite the recent rise in academic and practitioner interest in personalized 
medicine development (Amir-Aslani and Mangematin, 2010; Jørgensen, 2011; Tutton, 
2012; McClellan et al., 2013), no study has assessed the corporate capability of 
personalized medicine development in the pharmaceutical industry (PMD capability). 
Therefore, it is important that increased research efforts be devoted to developing a 
valid measure to evaluate that capability, which can be considered a useful tool in the 
pharmaceutical industry. 
Based on the previously gap in the literature (see Chapters 1 and 2 for details), a 
research question was raised: What are the key factors and how do these key factors 
affect corporate capability of personalized medicine development in pharmaceutical 
firms? In order to address this research question, in this chapter, a study aiming to 
develop a model illustrating PMD capability using several key influencing factors is 
conducted (Haruya and Kano, 2015). 
The study scheme is organized as shown in Figure 15. First, three factors are 
defined to illustrate PMD capability. Second, several hypotheses are formulated and 
observed variables are collected to develop a research model called the PMD capability 
model. Finally, in order to validate the research model, empirical analysis is conducted 
using structural equation modeling (SEM). 
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Figure 15.  Chapter 3 scheme (source: Haruya, original) 
3.2. Methodology 
3.2.1. Definition of PMD capability 
Here, the first question to solve is how to define PMD capability. In previous 
studies, the clearest definition is to recognize development capability as the number of 
products that have reached the market (Hoang and Rothaermel, 2010; Graves and 
Langowits, 1993; Deeds and Hill, 1996; Bierly and Chakrabarti, 1996). When 
discussing the capability for developing general products, this definition seems 
reasonable. However, it is difficult to follow the same method for drugs categorized as 
personalized medicine because there are insufficient cases of successful launches of 
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these kinds of products. Therefore, it is assumed using the number of launched 
products as the dependent variable when discussing PMD capability is inappropriate. 
Moreover, when discussing corporate capability of product development, the 
number of patents is sometimes utilized as a measure (Bierly and Chakrabarti, 1996; 
Rothaermel and Deeds, 2004). Thus, the number of patents related to biomarker 
knowledge could act as another definition of PMD capability. However, the number of 
patents was not used in this study since it was difficult to identify what patent belonged 
to a particular pharmaceutical company or product using public databases (Millonig, 
2015). 
In contrast, with the recent growth in technologies such as proteomics, 
metabolomic analysis, genetic testing, and molecular medicine, there has been a rapid 
rise in the number of personalized medicine products under development in the 
pharmaceutical industry (Love et al., 2012; PricewaterhouseCoopers 2009, 2011). 
Thus, the decision was made to focus on activities in the clinical development stage. 
Consequently, in this study, PMD capability is defined as the number of pipelines for 
drugs seeking a drug–CoDx combination. 
 
3.2.2. Definition of PMD capability key factors 
As described earlier, new product development is a key strategic activity in many 
firms because new products significantly contribute to sales. Some published articles 
have described measures for the corporate capability of NPD (NPD capability) in the 
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pharmaceutical industry. For example, Deeds et al. (1999) suggested that NPD 
capability could be measured by a firm’s location, scientific capabilities, external 
contacts, and the functional and educational backgrounds of top managers (Deeds et al., 
2000). Additionally, Bierly and Chakrabarti (1996) described NPD capability by 
focusing on two fundamental constructs: technological learning (e.g., internal and 
external learning) and strategic flexibility (e.g., breadth of the knowledge base and 
financial, marketing, and manufacturing flexibility) (Bierly and Chakrabarti, 1996). 
It is clear that NPD capability is the first key factors influencing PMD capability. 
However, previously described NPD models are typically unsuitable to describe PMD 
capability because drugs and CoDx must be simultaneously developed for personal 
medicine development. Since there are two options for pharmaceutical companies to 
co-develop CoDx (i.e., via external partnerships or in-house cooperation), the second 
and third key influencing factors for PMD capability are defined as corporate 
capability of CoDx co-development with external parties (External CoDxD capability) 
and corporate capability of CoDx co-development with an internal organization 
(Internal CoDxD capability), respectively. 
 
3.2.3. Hypotheses 
Based on the definitions of the three key influencing factors illustrating PMD 
capability (i.e., NPD capability, External CoDxD capability, and Internal CoDxD 
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capability), six hypotheses and a research model (the PMD capability model) (Figure 
16), were developed as follows: 
 Hypothesis 1: NPD capability has a positive effect on PMD capability 
 Hypothesis 2: NPD capability has a positive effect on External CoDxD 
capability 
 Hypothesis 3: External CoDxD capability has a positive effect on PMD 
capability 
 Hypothesis 4: NPD capability has a positive effect on Internal CoDxD 
capability 
 Hypothesis 5: Internal CoDxD capability has a positive effect on PMD 
capability 
 Hypothesis 6: Internal CoDxD capability has a positive effect on External 
CoDxD capability 
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Figure 16.  The PMD capability model (source: Haruya and Kano, 2015) 
 
Firstly, it was hypothesized that there are two ways to show the effect from NPD 
capability to PMD capability: direct and indirect effects. The direct effect was 
described as the path from NPD capability to PMD capability. Thus, Hypothesis 1 was 
formulated to test whether or not it is appropriate to measure PMD capability using 
only NPD capability. 
In contrast, the indirect effects related to CoDx co-development capability can be 
measured by both external partnerships and in-house cooperation. Consequently, the 
former was described as the path from NPD capability to PMD capability via External 
CoDxD capability, while the latter was described as the path via Internal CoDxD 
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capability. Therefore, Hypotheses 2–5 were formulated to test the validity of these 
effects. 
As previously discussed, one of the most important actions for successful CoDx 
co-development is initiating pharmaceutical and diagnostic organization collaboration 
in an early stage of drug development (Jørgensen, 2012; Moore et al., 2012). In 
addition, trust, harmonized goals, and clear communication at all levels is crucial to 
collaboration success for both external and internal business partnerships. As such, the 
advantage of in-house cooperation might be that it can overcome issues with regard to 
the overall value of the CoDx co-development process compared with external 
partnerships. Therefore, Internal CoDxD capability can be thought to have a stronger 
effect on PMD capability than External CoDxD capability. 
Finally, it was hypothesized that a pharmaceutical company with Internal CoDxD 
capability should have in-depth knowledge regarding successful CoDx co-development 
collaboration, which is important for partnerships with diagnostics companies. Hence, 
Hypothesis 6 was formulated to test if there is a positive effect from Internal CoDxD 
capability to External CoDxD capability. 
 
3.2.4. Observed variables 
PMD capability, NPD capability, External CoDxD capability, and Internal CoDxD 
capability can be considered as latent variables, and observed variables need to be 
linked each latent variable in order to validate the developed research model using a 
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statistical procedure. Figure 17 presents the PMD capability model that includes 
observed variables. 
 
 
Figure 17.  The PMD capability model with observed variables (source: Haruya and 
Kano, 2015) 
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PM pipelines 
As described earlier, PMD capability is defined as the number of pipelines for 
drugs that seek a drug–CoDx combination. In this study, it was termed as PM pipelines, 
which is defined as an observed variable for PMD capability. Although a number of 
drugs have recently been co-developing with CoDx in the preclinical development 
stage or phase I, the pipelines used for investigations in this study were limited to those 
in phases II and III in order to exclude products under exploratory development. 
 
Drug pipelines 
In the pharmaceutical industry, the number of drugs under development is a 
common indicator of technological competence or expertise (Deeds et al., 1997). The 
amount and types of new drugs in a company’s drug pipeline reveal the firm’s current 
NPD capabilities to the market. Thus, the variable Drug pipelines was defined as the 
first observed variable that could be affected by NPD capability. Data for this variable 
were established as the number of drugs under development during phases I–III as of 
December 2012. 
 
Approved drugs 
Similar to the number of drugs under development, the number of drugs that have 
reached the market is also frequently used as an indicator of NPD capability (Graves 
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and Langowits, 1993; Deeds and Hill, 1996; Bierly and Chakrabarti, 1996). Hence, the 
variable Approved drugs was defined as the second observed variable that could be 
affected by NPD capability. Given the number of mergers and acquisitions in the 
pharmaceutical industry in the first decade of 2000 (e.g., Glaxo Wellcome and 
SmithKline Beecham in 2000, Aventis and Sanofi-Synthélabo in 2004, and Pfizer and 
Wyeth in 2009), to represent this variable, data about the capabilities of existing 
companies included the number of U.S. FDA-approved drugs from January 2010 to 
December 2012. 
 
CoDx deals 
Recently, the rising number of CoDx partnerships between pharmaceutical and 
diagnostics companies has highlighted the increasing number of pharmaceutical firms 
that are seriously considering the need for biomarker and diagnostic programs to 
accompany their drug development efforts (PricewaterhouseCoopers, 2009, 2011). 
Therefore, the variable CoDx deals was used to describe the number of CoDx 
partnerships and was defined as potentially being affected by External CoDxD 
capability. For the same reason as Approved drugs, these data were gathered from 
January 2010 to December 2012. 
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In-house IVD organization 
In this regard, whether or not a firm has an in-house IVD organization can be 
another important observed variable. Although there are differences in the relative 
capabilities of in-house organizations (PricewaterhouseCoopers, 2011), this study 
focused on whether or not the investigated pharmaceutical company has its own 
in-house IVD organization. For this, the dummy variable In-house IVD organization 
was adopted, and was assigned a value of 1 for the presence of an in-house IVD 
organization and 0 for an absence. In-house IVD organization was defined as an 
observed variable of Internal CoDxD capability. 
 
Oncology pipelines 
Especially in oncology, CoDx developments are considered crucial for the 
corresponding drugs compared with other major therapeutic diseases in terms of 
scientific potential and economic attractiveness (Davis et al., 2009; Winther and 
Jørgensen, 2010; Papadopoulos et al., 2006; Ong et al., 2012). Indeed, most approved 
drugs that require performing CoDx assays can be categorized as oncology-related 
(Cheng et al., 2012; Fridlyand et al., 2013; PricewaterhouseCoopers, 2009, 2011; 
Simon, 2013; Winther and Jørgensen, 2010). Therefore, the number of oncology drugs 
under development can be considered disease-specific knowledge for personalized 
medicine, which can be influenced by CoDx co-development capability. In this regard, 
Oncology pipelines was defined as an observed variable of both External and Internal 
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CoDxD capability, enabling SEM analysis to include an element of exploratory factor 
analysis. The data for this variable were gathered as the number of drugs in phases I–
III as of December 2012. 
 
Approved PM 
To date, several drugs that require performing CoDx assays before administration 
have been approved by the U.S. FDA (FDA, 2013). Although drugs categorized as 
personalized medicine are now attracting increased attention from various research 
fields, this is still a new trend in drug development, and there are a limited number of 
cases of successful launches (FDA, 2013). As such, these achievements can be 
considered precious experience in personalized medicine development, which may be 
influenced by CoDx co-development capability. With this in mind, Approved PM was 
also defined as an observed variable of both External and Internal CoDxD capability to 
allow for the incorporation of exploratory factor analysis within SEM analysis. The 
data for this variable were gathered as the total number of U.S. FDA-approved drugs 
that require performing CoDx assays as of December 2012. 
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3.3. Data and sample 
This study’s sample focused on pharmaceutical companies which global sales in 
2012 were linked in top 20 and considered to have personalized medicine development 
activities based on the data (i.e., they all had more than one PM pipeline, approved PM, 
or CoDx deal). As a result, 15 companies (i.e., Abbott Laboratories, Amgen, Astellas, 
AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & 
Johnson, Merck & Co., Novartis, Pfizer, Roche, Sanofi, and Takeda) were selected as 
the study sample. All data were obtained from published articles or reports, company 
prospectuses, or the U.S. FDA website. The definitions and values for each observed 
variable are presented in Table 6 and Table 7, respectively. 
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Table 6.  Definitions of the observed variables (source: Haruya and Kano, 2015) 
Variable Definition 
PM pipelines 
The number of pipelines in phases II–III for drugs that are 
co-developing with CoDx as of December 2012 
Drug pipelines 
The number of pipelines in phases I–III for all drugs as of 
December 2012 
Approved drugs 
The number of approved drugs in all countries from January 
2010 to December 2012 
CoDx deals 
The published number of deals between pharmaceutical and 
diagnostics companies related to CoDx partnerships from 
January 2010 to December 2012 
In-house IVD 
organization 
Presence or absence of an in-house IVD development division 
or business unit as of December 2012 (1 = presence, 0 = 
absence) 
Oncology pipelines 
The number of pipelines in phases I–III for oncology drugs as 
of December 2012 
Approved PM 
The number of U.S. FDA-approved drugs that require CoDx 
assays as of December 2012 
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Table 7.  Values of the observed variables (source: Analyzed based on published articles or reports, company corporate annual reports, 
or the U.S. FDA website, as of December 2012) 
Pharmaceutical 
companies 
PM 
pipelines 
Drug 
pipelines 
Approved 
drugs 
CoDx 
deals 
In-house IVD 
organization 
Oncology 
pipelines 
Approved 
PM 
Abbott Laboratories 1 43 26 0 1 16 0 
Amgen 1 47 10 2 0 25 1 
Astellas 1 47 31 2 0 15 0 
AstraZeneca 3 79 31 3 0 28 0 
Bayer 0 46 30 1 1 17 0 
Bristol-Myers Squibb 0 66 31 5 0 21 1 
Eli Lilly 1 81 18 1 0 37 1 
GlaxoSmithKline 6 138 64 3 0 23 2 
Johnson & Johnson 1 73 38 0 1 12 0 
Merck & Co. 0 91 47 2 0 25 0 
Novartis 3 117 66 1 1 36 2 
Pfizer 2 90 58 6 0 18 2 
Roche 7 103 46 7 1 55 4 
Sanofi 1 83 56 2 0 22 1 
Takeda 1 53 58 2 0 20 0 
Mean ± SD 1.9 ± 2.1 77.1 ± 28.1 40.7 ± 17.2 2.5 ± 2.1 0.3 ± 0.5 24.7 ± 11.0 0.9 ± 1.2 
Note: see Appendix 3 for additional information of samples 
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3.4. Structural equation modeling analysis 
3.4.1. Rationale for using structural equation modeling 
analysis 
There are several methods that can be used to estimate relationships among 
variables (Kleinbaum et al., 2013). When the focus is on the relationship between a 
dependent variable and one or more independent variables, regression analysis is 
typically one of the most popular methods. However, regression analysis cannot be 
used when the goal is to measure relationships among the factors. Moreover, since 
there is moderate correlation among observed variables in this study (Table 8), as a 
means of reducing multicollinearity, it is necessary to remove some variables if 
regression analysis is selected. Therefore, it is considered that regression analysis is not 
an appropriate method in this study, and it is necessary to find a statistical tool that can 
estimate causal relationship among factors. 
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Table 8.  Correlation among variables 
 
PM 
pipelines 
Drug 
pipelines 
Approved 
drugs 
CoDx deals 
In-house 
IVD 
organization 
Oncology 
pipelines 
Approved 
PM 
PM pipelines 1.000 
      
Drug pipelines 0.707** 1.000 
     
Approved drugs 0.417 0.680** 1.000 
    
CoDx deals 0.509 0.337* 0.247 1.000 
   
In-house IVD 
organization 
0.186 -0.019 0.023 -0.236 1.000 
  
Oncology 
pipelines 
0.642** 0.489* 0.085 0.448* 0.169 1.000 
 
Approved PM 0.786** 0.654** 0.376 0.698** 0.168 0.747** 1.000 
*: p < 0.1, **: p < 0.01 
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Structural equation modeling (SEM) is a statistical technique that can test a 
conceptual or theoretical model by estimating causal relations among factors (latent 
variables) using observed variables (Figure 18). SEM analyses include factor analysis, 
regression/path analysis, and latent growth modeling (Kline, 2010). The term 
‘structural equation model’ most commonly refers to a combination of two elements: a 
‘measurement model’ that defines latent variables using one or more observed 
variables, and a ‘structural regression model’ that links latent variables together. In 
addition, it allows for analysis of complex networks of constructs and indicates how a 
research model based on strong theoretical knowledge fits the data by estimating 
overall goodness-of-fit measures (Schermelleh-Engel et al., 2003; Bol et al., 2010; 
Tomarken and Waller, 2005). 
Therefore, this method fits the objectives of this study. Consequently, SEM 
analysis conducted with the AMOS 21 program (IBM) (Arbuckle, 2007) was selected 
as the analytical method used to demonstrate the validity of the PMD capability model. 
 
 
Figure 18.  Concept of structural equation modeling (SEM) analysis (source: Haruya, 
original) 
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3.4.2. Estimation method and goodness-of-fit chose 
for structural equation modeling analysis 
In this study, maximum likelihood estimation was employed to test the 
goodness-of-fit of the model using SEM analysis. In addition, because there is no 
single universally accepted criterion to judge model fit (Heubeck and Neill, 2000), 
several widely accepted goodness-of-fit indexes were used (Table 9): comparative fit 
index (CFI), goodness-of-fit index (GFI), root mean square residual (RMR), and root 
mean square error of approximation (RMSEA). 
CFI implies an improvement in the target model’s fit compared with the baseline 
model, with recommended values of greater than 0.97 (Schermelleh-Engel et al., 2003; 
Bol et al., 2010; Tomarken and Waller, 2005). GFI implies testing how much better the 
model fits compared with ‘no model at all.’ Typically, values greater than 0.90 indicate 
an acceptable fit for this index (Schermelleh-Engel et al., 2003; Bol et al., 2010; 
Tomarken and Waller, 2005). RMR is an overall badness-of-fit measure that assesses 
the average differences between the values predicted by a model and the values 
actually observed in the sample. Here, values lower than 0.05 indicate a good model fit 
(Schermelleh-Engel et al., 2003; Bol et al., 2010; Tomarken and Waller, 2005). Finally, 
RMSEA indicates the lack of fit in a model compared with a perfect model. Therefore, 
for a close fit, the value needs to be small (i.e., up to 0.05) to represent a close fit 
(Schermelleh-Engel et al., 2003; Bol et al., 2010; Tomarken and Waller, 2005). 
 
  
Corporate Capability for Personalized Medicine Development 
The University of Tokyo, Mei Haruya 
79 
Table 9.  Selected indexes to estimate goodness-of-fit of the model (source: 
Schermelleh-Engel et al., 2003; Bol et al., 2010; Tomarken and Waller, 2005) 
Goodness-of-fit indexes Value indicated good fit of the model 
Comparative fit index (CFI) > 0.97 
Goodness-of-fit index (GFI) > 0.90 
Root mean square residual (RMR) < 0.05 
Root mean square error of approximation 
(RMSEA) 
< 0.05 
3.5. Results 
Firstly, Table 10 presents the values of each index from the SEM analysis in this 
study. It is clear that all indexes showed a value greater than the described thresholds, 
implying that the hypothesized research model exhibited a good overall fit. 
 
Table 10.  Results of goodness-of-fit (source: Haruya and Kano, 2015) 
Goodness-of-fit indexes Results 
Value indicated as good 
fit of the model 
Comparative fit index (CFI) 1.00 > 0.97 
Goodness-of-fit index (GFI) 0.903 > 0.90 
Root mean square residual (RMR) 0.050 < 0.05 
Root mean square error of 
approximation (RMSEA) 
0.000 < 0.05 
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Next, the results of all hypothesized paths in the PMD capability model are 
presented in Figure 19. The paths between the latent and observed variables showed 
strong effects (path coefficient > 0.5) and were statistically significant (p < 0.05). The 
only exceptions were the non-significant path from Internal CoDxD capability to 
Oncology pipelines, while the path from Internal CoDxD capability to Approved PM 
showed weak effects (path coefficient = 0.49). 
In terms of the paths from NPD capability to External CoDxD capability 
(Hypothesis 2) and from External CoDxD capability to PMD capability (Hypothesis 3), 
the results were statistically significant (p < 0.05), with path coefficients of 0.58 and 
0.57, respectively. This implied a strong positive influence from NPD capability to 
External CoDxD capability and from External CoDxD capability to PMD capability, 
supporting Hypotheses 2 and 3. 
Although the path from Internal CoDxD capability to PMD capability (Hypothesis 
5) was statistically significant (p < 0.1), its path coefficient was 0.37. Thus, the path 
was supported, but there was only a weak influence of Internal CoDxD capability and 
PMD capability. 
In contrast, neither statistically significant nor strong influences could be 
confirmed for Hypotheses 1, 4, and 6. Specifically, the path from NPD capability to 
PMD capability revealed a path coefficient of 0.33 (p = 0.20), while that from NPD 
capability to Internal CoDxD capability was -0.02 (p = 0.92). Additionally, the path 
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from Internal CoDxD capability to External CoDxD capability was -0.29 (p = 0.32). 
Therefore, SEM analysis did not support these paths. 
 
 
Figure 19.  Results of SEM analysis (source: Haruya and Kano, 2015. See Appendix 
4, Appendix 5, Appendix 6, and Appendix 7 for details) 
 
  
Corporate Capability for Personalized Medicine Development 
The University of Tokyo, Mei Haruya 
82 
3.6. Discussion 
In this study, a model was developed to illustrate PMD capability using three key 
influencing factors: NPD capability, External CoDxD capability, and Internal CoDxD 
capability. Then, six hypotheses were developed and the causal relationships between 
the factors and PMD capability as well as among the factors were analyzed using SEM 
analysis. Overall, SEM analysis indicated a good fit for the model, and three 
noteworthy findings were obtained. 
 
3.6.1. Relationship between PMD capability and NPD 
capability 
The first finding pertains to the relationship between PMD capability and NPD 
capability. Although two types of effects on PMD capability from NPD capability 
were hypothesized, analysis revealed only an indirect effect. In particular, this effect 
occurred via External CoDxD capability, as confirmed in the results of the hypothesis 
tests (Figure 20). 
This finding implied that robust NPD capability is a necessary but not sufficient 
condition for PMD capability. One possible reason for this result could be the 
pharmaceutical firms’ diverse business strategies. That means that it is clear that 
companies with a robust NPD capability have an advantage when developing 
personalized medicine. However, since there remain many challenges in this field 
(Ferrara, 2007; Moore et al., 2012; Jørgensen, 2011; Schmidt, 2012; Lehrach, 2012), 
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not all such companies can or want to invest resources into personalized medicine 
development. Consequently, it was indicated that key factors for personalized medicine 
development differ from those for traditional drug development.  
 
 
Figure 20.  Relationship between PMD capability and NPD capability (source: 
Haruya and Kano, 2015) 
 
3.6.2. Effect from external/internal CoDxD capability to 
Oncology pipelines and Approved PM 
The second finding is that Oncology pipelines and Approved PM were loaded 
much stronger by External CoDxD capability than by Internal CoDxD capability (i.e., 
the path from Internal CoDxD capability to Oncology pipelines was not statistically 
significant, while that to Approved PM showed a weak coefficient) (Figure 21). 
Corporate Capability for Personalized Medicine Development 
The University of Tokyo, Mei Haruya 
84 
Consequently, this result may imply that Oncology pipelines represent disease-specific 
knowledge for personalized medicine, while Approved PM may represent experience 
with personalized medicine development. Although such knowledge and experience 
are important when internally co-developing CoDx, it is reasonable to suppose that 
external partners place more importance on these observed variables. 
Based on the results presented herein, we can conclude that disease knowledge, 
experience with personalized medicine development, and collaboration on CoDx 
co-development are key components for External CoDxD capability. However, the 
only key component for Internal CoDxD capability is the presence of an in-house IVD 
organization. 
 
 
Figure 21.  Effect from External CoDxD capability and Internal CoDxD capability to 
the observed variables (source: Haruya and Kano, 2015) 
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3.6.3. Effect of External CoDxD capability and Internal 
CoDxD Capability to PMD Capability 
The last finding is that the effect of External CoDxD capability is stronger than 
Internal CoDxD capability, although it was confirmed that both External CoDxD 
capability and Internal CoDxD capability contribute to PMD capability (Figure 22). 
Based on previous studies (Cheng et al., 2012; Moore et al., 2012; Roche, 2011), it can 
be assumed that Internal CoDxD capability will have a stronger influence on PMD 
capability compared with External CoDxD capability since companies with an 
in-house IVD organization should more easily contribute to PMD capability than those 
that do not. Surprisingly, the results of hypothesis testing differed. Specifically, the 
result showed a path coefficient of 0.37 from Internal CoDxD capability to PMD 
capability, which implied that Internal CoDxD capability has a limited influence on 
PMD capability. In other words, the key factor to promoting CoDx co-development 
seems to be external partnerships rather than in-house cooperation. 
 
 
Figure 22.  Effect of External CoDxD capability and Internal CoDxD Capability to 
PMD Capability (source: Haruya and Kano, 2015) 
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One of the reasons for this result might be difficulty achieving successful CoDx 
co-development through simple reliance on one internal IVD organization. In CoDx 
development, various first-line technologies as well as flexible and cost-efficient 
platforms are necessary in order to meet the wide variety of drug development needs 
(Love et al., 2012; Moore et al., 2012). As a result, this makes it difficult for 
pharmaceutical companies that have in-house IVD development capability to cover all 
necessary resources for CoDx development. Consequently, Internal CoDxD capability 
does not significantly influence PMD capability. The same logic might explain why 
the path between Internal CoDxD capability and External CoDxD capability has 
neither a statistically significant nor a strong effect. 
 
3.6.4. Managerial implications 
Based on the results of SEM analysis, it was indicated that the critical path 
contributing to PMD capability is from NPD capability via External CoDxD capability 
(Figure 23). This implies that, regardless of whether or not pharmaceutical companies 
have an in-house IVD organization, increasing corporate capability in co-developing 
CoDx with external diagnostic firms is essential for personalized medicine 
development in the pharmaceutical industry. 
However, this does not mean that having strong corporate capability in in-house 
cooperation for CoDx co-development is negligible. That is, study results also showed 
that the path from Internal CoDxD capability to PMD capability was statistically 
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significant (p < 0.1), although its coefficient was small (0.37). Thus, the managerial 
implication of this finding is that having corporate capability in in-house cooperation is 
not sufficient for personalized medicine development. In other words, it appears that 
having an in-house IVD organization is not critical for the development of 
personalized medicine by pharmaceutical firms. Moreover, even for those firms that 
have an in-house IVD organization, it would be important for managements to 
continue to increase corporate capability in co-developing CoDx with external 
diagnostic firms for personalized medicine development in the pharmaceutical 
industry. 
 
 
Figure 23.  Critical paths in the PMD capability model (source: Haruya and Kano, 
2015) 
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Roche provides a good example when demonstrating this implication. Roche is a 
pharmaceutical company with an internal IVD organization (i.e., Roche Diagnostics), 
and is viewed as one of leading companies in the personalized medicine era 
(PricewaterhouseCoopers, 2009; 2011). 
Over the past decade, Roche has launched more than four new drugs that require 
CoDx testing before therapeutic treatment (Table 11). When the partners for CoDx 
co-development (i.e., CoDx manufacturers) are examined, it is evident that two of four 
cases were not corroborated with Roche Diagnostics. Thus, this provides clear 
evidence that even those pharmaceutical companies with internal IVD organization are 
collaborating with external diagnostic companies for CoDx development. 
 
Table 11.  Selected drugs launched by Roche (source: Roche corporate annual 
reports) 
Drugs CoDx CoDx Manufacturers 
Zelboraf Cobas 4800 BRAF V600 Mutation Test Roche Diagnostics 
Tarceba Cobas EGFR Mutation Test Roche Diagnostics 
Perjeta HER2 IQFISH PharmDx, HercepTest Dako 
Kadcyla HER2 IQFISH PharmDx, HercepTest Dako 
EGFR: Epidermal growth factor receptor; FISH: Fluorescence in situ hybridization; 
HER2: Human epidermal growth factor receptor 2 
 
This trend is also exciting during the development stages. According to the 2009 
and 2011 PricewaterhouseCoopers reports, Roche created 10 and 4 external CoDx 
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partnerships during 2004-2008 and 2009-2010, respectively (PricewaterhouseCoopers, 
2009; 2011). This implies that substantial personalized medicine development is 
currently occurring at Roche in collaboration with external diagnostic partners in 
addition to in-house cooperation of drug-CoDx development. 
3.7. Chapter 3 conclusion and next steps in 
Chapter 4 
In Chapter 3, PMD capability was defined as the number of pipelines for drugs 
seeking the drug–CoDx combination. Accordingly, three latent variables (i.e., NPD 
capability, External CoDxD capability, and Internal CoDxD capability) were defined 
as key influencing factors and a model was developed to illustrate PMD capability 
using six observed variables: Drug pipelines, Approved drugs, CoDx deals, In-house 
IVD organization, Oncology pipelines, and Approved PM. The proposed research 
model was then validated using SEM analysis, and the results indicated a good fit of 
the model and showed that the critical path toward PMD capability is from NPD 
capability via External CoDxD capability. 
In this chapter, a major contribution was made to understanding corporate 
capability of personalized medicine development from the perspective of 
pharmaceutical firms. Particularly, the study provided a clear answer to arguments 
regarding the options to access CoDx co-development (i.e., corporate capability of 
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CoDx co-development with external parties would be essential for personalized 
medicine development in the current pharmaceutical industry) through quantitative 
analysis. Therefore, from a scientific and business strategy perspective, it can be 
suggested that the management of all pharmaceutical companies continue to seek 
opportunities for crucial external partnerships, regardless of whether or not the 
company has an in-house IVD organization. 
In contrast, in order to further clarify capability in synchronized co-development, 
it is also important to establish greater understanding from the perspective of 
diagnostic firms. Therefore, Chapter 4 will focus on illustrating corporate capability of 
personalized medicine development based on diagnostic firm capability. 
3.8. Limitations 
In previous studies, one of the clearest definitions for development capability was 
the number of products that have reached the market (Hoang and Rothaermel, 2010; 
Graves and Langowits, 1993; Deeds and Hill, 1996; Bierly and Chakrabarti, 1996). 
However, in this study, instead of utilizing this existing definition, PM pipelines (i.e., 
the number of drugs under clinical development seeking a drug–CoDx combination) 
was selected as the observed variable for PMD capability. The reason the number of 
personalized medicines that have reached the market was not used as the definition of 
PMD capability is because there are insufficient cases of successful launches of these 
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products. Therefore, it is assumed that the use of this number is inappropriate. 
Consequently, the focus of this study was on activities in the clinical development 
stage and the observed variable for PMD capability was defined the number of 
pipelines for drugs that seek a drug–CoDx combination. 
I believe that this is currently the most reasonable way to illustrate PMD capability 
because personalized medicine development is still a new trend. However, when the 
market matures and more samples are available, the definition of observed variable for 
PMD capability could be reverted to launched personalized medicine, as defined in 
previous works. Therefore, PM pipelines should be used as definition of PMD 
capability only at this point in time. 
Similarly, the total number of PM pipelines in each company is currently limited, 
and personalized medicine development trends could dramatically change over time. 
Therefore, the results obtained from this study should be limited to trend analysis in 
the early 2010s. As a result, future research could reassess these trends following the 
maturation of personalized medicine in the pharmaceutical industry. 
At that time, it may be possible to divide PM pipelines into discovery, phase I, II, 
and III stages. This would facilitate a deeper understanding of the actual condition of 
personalized development in the pharmaceutical industry. 
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Appendix 1.  Data of Figure 2 
 
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
The number of studies 
including biomarker 
assessments 
85 148 180 287 328 392 481 487 567 627 539 554 441 
The number of all of 
studies 
1572 2191 2824 3758 4377 5055 5344 5843 6082 6105 6305 6007 4802 
Rate of studies 
including biomarker 
assessments 
5 7 6 8 7 8 9 8 9 10 9 9 9 
Note: reduction of the number of studies including biomarker assessments during last few years could be because the delay of 
publication of study information into ClinicalTrials.gov. 
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Appendix 2.  The pros and cons of chief technologies commonly adopted for CoDx (source: Rajan et al., 2011) 
CoDx Technologies Definition Pros Cons 
Immunohistochemistry (IHC) Method of determining if 
specific antigen is present in 
tissues by staining antibodies 
with markers such as fluorescent 
dyes or enzymes. 
Well established, routinely used 
technology; relatively 
inexpensive; relatively rapid 
turnaround time with availability 
of automated systems; shows 
exact location of protein within 
tissue; largely used on fixed 
tissues, cell morphology 
preserved and antibodies not 
displaced. 
Not quantitative: no direct 
correlation between staining and 
amount of protein; false positive 
possibility when fluorescence is 
not limited to a specific cell 
type; low reproducibility; cannot 
distinguish between expression 
due to gene amplification versus 
other, non-genetic causes; 
accuracy depends on antibody 
employed (monoclonal vs. 
polyclonal) 
Fluorescence in situ 
hybridisation (FISH) 
Cytogenetic technology that uses 
fluorescent or colorimetric 
probes to detect and localize the 
presence or absence of specific 
DNA sequence alterations such 
as translocations and 
amplifications on chromosomes. 
Independent of antibody, 
provides unambiguous evidence 
of genetic alterations, highly 
sensitive and specific to target 
sequence; quantitative; direct 
detection, thereby faster; easily 
detected with many color 
systems; relatively large number 
of cells can be analyzed. 
Requires expensive, specialized 
equipment; relatively time 
consuming and expensive as 
results tend to be recorded with 
camera; fluorescent signals 
likely to fade; requires 
significant experience to 
interpret data. 
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CoDx Technologies Definition Pros Cons 
qPCR Technique based on PCR that 
detects/amplifies a specific gene 
or transcript and quantifies the 
amplified molecules as they 
accumulate in real-time during 
the PCR amplification process. 
Starting to become well 
established, standardized 
technology; very sensitive; 
quantitative (fluorescent signal 
is directly proportional to the 
number of amplicons generated); 
large dynamic range; detection 
platforms have quick turnaround 
time; automated and high 
throughput; closed reaction: no 
post-PCR processing with 
minimum cross contamination. 
Expensive; careful controls 
necessary to interpret data and 
avoid contamination; primer sets 
must be designed and validated 
stringently to ensure accuracy of 
results; results highly dependent 
on sample quality; cannot 
distinguish between a lot of cells 
with a little transcript or a few 
cells with a lot of transcript; can 
only provide information about 
the genes to which primer sets 
have been designed. 
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CoDx Technologies Definition Pros Cons 
Arrays Arrays are a multiplex 
lab-on-a-chip that consists of 
biological material hybridized to 
a solid surface or a bead bound 
probe in aqueous suspension. 
They are used for applications 
such as profiling gene 
expression, comparing genomic 
hybridization and detecting 
single nucleotide 
polymorphisms. 
Massive, parallel, 
high-throughput interrogation of 
many genes; miniaturisation; 
cost effective; patterns of gene 
expression can be useful for 
prognostication. 
CoDx tests generally need to 
interrogate only one or a few 
genes per sample and arrays may 
be excessive for this purpose; 
requires careful controls to 
ensure reproducibility; semi 
quantitative; not as sensitive as 
qPCR; labor intensive, requiring 
distinct sample preparation and 
amplification steps; only detects 
unbalanced rearrangements and 
not balanced translocations or 
inversions; can only provide 
information about the genes that 
are included on the array. 
Traditional DNA sequencing Technology used to determine 
the primary structure (i.e., 
sequence of nucleotides) of 
DNA. Genes amplified by PCR, 
chain termination methods are 
used to determine the sequence 
of the entire DNA. 
Extensive detection of somatic 
mutations; key if target gene can 
be mutated in multiple different 
ways; no a priori knowledge of 
mutation or of gene of interest 
required. 
Expensive; time consuming and 
labor intensive; not as sensitive 
as qPCR (requires the mutation 
to be present in at least 20% of 
the sample); does not detect 
certain mutations such as 
deletions. 
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Appendix 3.  Additional information of sample (source: Cegedim Strategic Data, 2011; 2012; corporate websites, 2011; 2012) 
Pharmaceutical 
companies 
Nation No. of employees 
Sales in 2011 
(million USD) 
R&D expenses 
in 2011 
(million USD) 
Sales in 2010 
(million USD) 
R&D expenses 
in 2010 
(million USD) 
Abbott Laboratories USA 91,000 22,435 4,129 19,894 3,725 
Amgen USA 17,800 15,582 3,116 15,053 2,894 
Astellas Japan 17,085 12,523 2,452 11,697 2,665 
AstraZeneca UK 57,200 32,981 5,523 32,515 5,318 
Bayer Germany 111,800 13,774 2,015 14,136 2,717 
Bristol-Myers 
Squibb 
USA 27,000 21,244 3,839 19,484 3,566 
Eli Lilly USA 38,442 22,608 5,021 21,685 4,884 
GlaxoSmithKline UK 97,389 34,293 6,045 36,167 6,351 
Johnson & Johnson USA 118,000 24,368 5,138 22,396 4,432 
Merck & Co. USA 86,000 41,289 8,467 39,811 10,991 
Novartis Switzerland 123,686 47,925 9,583 41,994 8,262 
Pfizer USA 57,400 57,747 9,112 58,523 9,413 
Roche Switzerland 80,127 36,439 7,632 39,389 8,673 
Sanofi France 113,719 40,607 6,041 39,515 5,832 
Takeda Japan 30,814 17,556 3,642 15,541 3,542 
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Appendix 4.  Details of SEM analysis result (Output path diagram) 
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Appendix 5.  Details of SEM analysis result (Regression Weights) 
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Appendix 6.  Details of SEM analysis result (Standardized Regression Weights) 
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Appendix 7.  Details of SEM analysis result (Factor Score Weights – Estimates) 
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